[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 63 of about 63
1. Rasic-Milutinovic Z, Perunicic G, Pljesa S, Gluvic Z, Ilic M, Stokić E: Metabolic syndrome in HD patients: association with body composition, nutritional status, inflammation and serum iron. Intern Med; 2007;46(13):945-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolic syndrome in HD patients: association with body composition, nutritional status, inflammation and serum iron.
  • OBJECTIVE: Insulin resistance and metabolic syndrome (MeS) are common in end-stage renal disease (ESRD) patients on maintenance hemodialysis (HD).
  • Such metabolic and clinical abnormalities may lead to an increased risk for cardiovascular disease.
  • Logistical regression analysis was used to evaluate the correlation between measured variables and the presence of MeS in HD patients.
  • RESULTS: After adjustment for confounding variables, a model consisting of serum levels of iron, transferrin saturation (TSAT), and BMI which accounted for 62% of the variance in MeS, determined only BMI as an independent marker (according to ATP-III criteria).
  • CONCLUSION: The present study demonstrated that serum iron participated together with independent predictors, glucose and BMI, in the pathogenesis of IR and MeS of ESRD patients on maintenance HD.
  • [MeSH-minor] Adult. Analysis of Variance. Blood Glucose / analysis. Body Composition. Body Mass Index. Cardiovascular Diseases / prevention & control. Case-Control Studies. Cohort Studies. Female. Follow-Up Studies. Humans. Incidence. Inflammation / diagnosis. Inflammation / epidemiology. Logistic Models. Male. Middle Aged. Nutritional Status. Predictive Value of Tests. Risk Factors. Severity of Illness Index. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • MedlinePlus Health Information. consumer health - Metabolic Syndrome.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17603231.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Blood Glucose; 9007-41-4 / C-Reactive Protein; 9007-73-2 / Ferritins
  •  go-up   go-down


2. Madsen LH, Ladefoged S, Corell P, Schou M, Hildebrandt PR, Atar D: N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis. Kidney Int; 2007 Mar;71(6):548-54
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis.
  • In patients with end-stage renal disease (ESRD) in hemodialysis (HD), levels of NT-proBNP are almost always raised.
  • In ESRD patients undergoing HD, we aimed at (i) identifying the factors that affect levels of NT-proBNP, (ii) determining the effect of HD on NT-proBNP, and (iii) determining the prognostic impact of NT-proBNP.
  • Serum NT-proBNP was measured before and after HD (Elecsys 2010).
  • NT-proBNP levels were markedly elevated (pre-HD 4079 pg/ml, post-HD 2759 pg/ml, P<0.001).
  • Patients with higher concentrations, both pre- and post-HD had an increased mortality rate compared to those with lower concentrations (P=0.007, P=0.002).
  • We found age (P=0.009) and NT-proBNP (pre-HD P=0.007, post-HD P=0.001) predictive of death.
  • Our findings demonstrate that CV disease in terms of LVH and reduced LVEF in addition to 24-h urine production and K(t)/V determine NT-proBNP levels.
  • Post-HD levels of NT-proBNP were lower than pre-HD levels; both predictive of mortality.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers / blood. Cardiovascular Diseases / blood. Cardiovascular Diseases / diagnosis. Cardiovascular Diseases / etiology. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Prognosis. Regression Analysis. Risk Factors. Stroke Volume / physiology. Ventricular Dysfunction, Left / blood. Ventricular Dysfunction, Left / diagnosis. Ventricular Dysfunction, Left / etiology

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Kidney Int. 2007 Mar;71(6):481-3 [17344896.001]
  • (PMID = 17299526.001).
  • [ISSN] 0085-2538
  • [Journal-full-title] Kidney international
  • [ISO-abbreviation] Kidney Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Peptide Fragments; 0 / pro-brain natriuretic peptide (1-76); 114471-18-0 / Natriuretic Peptide, Brain
  •  go-up   go-down


3. Yamasaki H, Sandrof MA, Boekelheide K: Suppression of radiation-induced testicular germ cell apoptosis by 2,5-hexanedione pretreatment. I. Histopathological analysis reveals stage dependence of attenuated apoptosis. Toxicol Sci; 2010 Oct;117(2):449-56

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suppression of radiation-induced testicular germ cell apoptosis by 2,5-hexanedione pretreatment. I. Histopathological analysis reveals stage dependence of attenuated apoptosis.
  • 2,5-Hexanedione (HD) and x-radiation (x-ray) are testicular toxicants, each with a unique cellular target.
  • HD exposure disrupts microtubule function in Sertoli cells, and x-ray exposure causes double-strand breaks in the DNA of germ cells.
  • In this study, adult male F344 rats were exposed to 1% HD in the drinking water for 18 days with or without coexposure to 2 or 5 Gy x-ray 12 h prior to necropsy.
  • Incidence of retained spermatid heads was increased in the HD and coexposure groups.
  • There was a striking stage-dependent attenuation of apoptosis with coexposure compared with x-ray alone.
  • Detailed histopathological analysis revealed a significant suppression of x-ray-induced germ cell apoptosis by HD pretreatment in stages I-VI of the seminiferous cycle, most noticeably at stages II/III.
  • We hypothesize either that subacute HD pretreatment compromises the ability of the Sertoli cells to eliminate x-ray-damaged germ cells or that germ cells are more resistant to x-ray-induced damage, having adapted to a less supportive environment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Soc Exp Biol Med. 2000 Nov;225(2):105-15 [11044252.001]
  • [Cites] Toxicol Sci. 2010 Oct;117(2):457-65 [20616210.001]
  • [Cites] Toxicol Sci. 2004 Jul;80(1):92-100 [15141104.001]
  • [Cites] Biol Reprod. 1983 Aug;29(1):257-70 [6615968.001]
  • [Cites] Toxicol Appl Pharmacol. 1988 Jan;92(1):18-27 [3341024.001]
  • [Cites] Toxicol Appl Pharmacol. 1996 Apr;137(2):141-8 [8661338.001]
  • [Cites] J Androl. 1996 Jul-Aug;17(4):394-402 [8889702.001]
  • [Cites] Radiat Res. 1997 Apr;147(4):457-67 [9092926.001]
  • [Cites] Endocrinology. 1997 May;138(5):2081-8 [9112408.001]
  • [Cites] Tissue Cell. 1997 Aug;29(4):487-93 [9281847.001]
  • [Cites] Endocrinology. 1999 Feb;140(2):852-8 [9927315.001]
  • [Cites] Endocrinology. 1999 Apr;140(4):1709-17 [10098507.001]
  • [Cites] Ann N Y Acad Sci. 1952 Nov 20;55(4):548-73 [13139144.001]
  • [Cites] J Natl Cancer Inst Monogr. 2005;(34):6-8 [15784812.001]
  • [Cites] Toxicol Sci. 2007 Jan;95(1):249-56 [17065434.001]
  • [Cites] Toxicol Pathol. 2007 Aug;35(5):719-27 [17763286.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jun 17;105(24):8315-20 [18544648.001]
  • [Cites] Toxicol Pathol. 2008 Jun;36(4):552-9 [18467684.001]
  • [Cites] Toxicol Sci. 2010 Oct;117(2):466-74 [20616204.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2003;43:125-47 [12471174.001]
  • (PMID = 20616207.001).
  • [ISSN] 1096-0929
  • [Journal-full-title] Toxicological sciences : an official journal of the Society of Toxicology
  • [ISO-abbreviation] Toxicol. Sci.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P42 ES013660; United States / NIEHS NIH HHS / ES / 5 P42 ES013660
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hexanones; 0 / Radiation-Protective Agents; 110-13-4 / 2,5-hexanedione
  • [Other-IDs] NLM/ PMC2940404
  •  go-up   go-down


Advertisement
4. Kim YB, Lee IJ, Kim SY, Kim JW, Yoon HI, Kim SW, Kim S, Kim YT, Suh CO, Kim GE: Tumor heterogeneity of FIGO stage III carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys; 2009 Dec 1;75(5):1323-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor heterogeneity of FIGO stage III carcinoma of the uterine cervix.
  • PURPOSE: The purpose of this study was to analyze tumor heterogeneity based on tumor extent and suggest reappraisal of the system of the International Federation of Gynecology and Obstetrics (FIGO) for Stage III carcinoma of the uterine cervix from a radiotherapeutic viewpoint.
  • METHODS AND MATERIALS: Between 1986 and 2004, 407 patients with FIGO Stage III (FIGO Stage IIIa in 19 and IIIb in 388) were treated with external beam radiotherapy (RT) and high-dose rate brachytherapy.
  • RESULTS: The complete response rate was 79.6%, and the 5-year overall survival rates for Stage IIIa and Stage IIIb carcinoma of the cervix were 82.1% and 54.8%, respectively.
  • To determine which parameters of tumor extent had an influence on prognosis for Stage IIIb patients, pelvic wall (PW) extension and hydronephrosis (HD) retained significance on multivariate analysis.
  • Stage IIIb patients were divided into three subgroups according to PW extension and HD: low risk (unilateral PW extension without HD), intermediate risk (HD without PW extension or bilateral PW extension without HD), and high risk (unilateral or bilateral PW extension with HD).
  • CONCLUSIONS: FIGO Stage III carcinoma of the cervix covers considerably heterogeneous subgroups according to tumor extent.
  • Before initiation of treatment, we suggest that physicians determine a tailored treatment policy based on tumor heterogeneity for each Stage III patient.
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adult. Aged. Aged, 80 and over. Brachytherapy / methods. Carcinoma, Large Cell / mortality. Carcinoma, Large Cell / pathology. Carcinoma, Large Cell / radiotherapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Chi-Square Distribution. Female. Humans. Middle Aged. Survival Rate. Treatment Outcome. Tumor Burden

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1605-6; author reply 1606-7 [20637983.001]
  • (PMID = 19467800.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Sutton G, Axelrod JH, Bundy BN, Roy T, Homesley HD, Malfetano JH, Mychalczak BR, King ME: Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study. Gynecol Oncol; 2005 Jun;97(3):755-63
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study.
  • RESULTS: Of 180 evaluable patients entered on the study with surgically staged III and IV endometrial carcinoma maximally debulked to less than 2 cm, 77 had typical endometrial adenocarcinoma and 103 had high-risk histology, either papillary serous or clear cell carcinoma.
  • Both histologic groups had similar distribution for performance status, para-aortic node positivity, site and extent of disease, and International Federation of Gynecology and Obstetrics (FIGO) stage.
  • No patient with gross residual disease survived.
  • CONCLUSION: Whole abdominal irradiation in maximally resected advanced endometrial carcinoma has tolerable toxicity, and it is suggested that the outcome may be improved by this adjunctive treatment in patients with completely resected disease.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Staging. Postoperative Care. Radiotherapy / adverse effects. Radiotherapy / methods. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15913742.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


6. De Diego-Balaguer R, Couette M, Dolbeau G, Dürr A, Youssov K, Bachoud-Lévi AC: Striatal degeneration impairs language learning: evidence from Huntington's disease. Brain; 2008 Nov;131(Pt 11):2870-81
HAL archives ouvertes. Full text from .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Striatal degeneration impairs language learning: evidence from Huntington's disease.
  • We studied 13 pre-symptomatic gene-carriers and 22 early stage patients of Huntington's disease (pre-HD), both characterized by a progressive degeneration of the striatum and 21 late stage patients Huntington's disease (18 stage II, two stage III and one stage IV) where cortical degeneration accompanies striatal degeneration.
  • When presented with a simplified artificial language where words and rules could be extracted, early stage Huntington's disease patients (stage I) were impaired in the learning test, demonstrating a greater impairment in rule than word learning compared to the 20 age- and education-matched controls.
  • Huntington's disease patients at later stages were impaired both on word and rule learning.
  • [MeSH-major] Corpus Striatum / pathology. Huntington Disease / psychology. Language. Learning
  • [MeSH-minor] Acoustic Stimulation / methods. Adult. Aged. Attention. Cognition Disorders / etiology. Cognition Disorders / psychology. Disease Progression. Female. Heterozygote. Humans. Language Tests. Magnetic Resonance Imaging / methods. Male. Memory, Short-Term. Middle Aged. Neuropsychological Tests. Semantics. Severity of Illness Index. Transfer (Psychology)

  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuropsychologia. 2006;44(2):275-88 [15964035.001]
  • [Cites] Behav Brain Res. 2006 Jan 30;166(2):189-96 [16153716.001]
  • [Cites] Nat Neurosci. 2006 Apr;9(4):562-8 [16501567.001]
  • [Cites] Nat Rev Neurosci. 2006 Jun;7(6):464-76 [16715055.001]
  • [Cites] Rev Neurol (Paris). 2006 Jun;162(6-7):721-8 [16840980.001]
  • [Cites] Curr Pharm Des. 2006;12(21):2701-20 [16842168.001]
  • [Cites] Neuroimage. 2006 Oct 1;32(4):1562-75 [16875847.001]
  • [Cites] J Cogn Neurosci. 2006 Sep;18(9):1555-69 [16989555.001]
  • [Cites] Neuropsychologia. 2007 Jan 28;45(2):305-20 [16978666.001]
  • [Cites] Neuroimage. 2007 Jun;36(2):431-40 [17462915.001]
  • [Cites] Psychol Sci. 2007 May;18(5):387-91 [17576276.001]
  • [Cites] Psychol Rev. 2007 Jul;114(3):632-56 [17638499.001]
  • [Cites] Neuroimage. 2007 Aug 1;37(1):8-17 [17560794.001]
  • [Cites] Am J Psychiatry. 2007 Sep;164(9):1428-34 [17728429.001]
  • [Cites] Cognition. 2007 Nov;105(2):247-99 [17083927.001]
  • [Cites] Hum Brain Mapp. 2007 Nov;28(11):1089-97 [17133392.001]
  • [Cites] PLoS One. 2007;2(11):e1175 [18000546.001]
  • [Cites] J Exp Psychol Learn Mem Cogn. 2008 Jan;34(1):80-96 [18194056.001]
  • [Cites] Neuropsychologia. 2008 Apr;46(5):1391-400 [18242648.001]
  • [Cites] Cereb Cortex. 2008 Jul;18(7):1496-505 [17947346.001]
  • [Cites] Neurology. 2000 Mar 14;54(5):1117-23 [10720284.001]
  • [Cites] Neuroscience. 2000;96(3):451-74 [10717427.001]
  • [Cites] J Psycholinguist Res. 2001 Jan;30(1):37-69 [11291183.001]
  • [Cites] Nature. 2001 Jun 21;411(6840):953-6 [11418860.001]
  • [Cites] J Psycholinguist Res. 2001 May;30(3):321-38 [11523277.001]
  • [Cites] Cognition. 2002 Feb;83(1):B13-23 [11814489.001]
  • [Cites] J Neurosci. 2002 Apr 1;22(7):2541-9 [11923419.001]
  • [Cites] Brain. 2002 Aug;125(Pt 8):1815-28 [12135972.001]
  • [Cites] J Neurosci. 2002 Aug 1;22(15):6756-65 [12151555.001]
  • [Cites] Neuron. 2002 Jul 18;35(2):371-81 [12160754.001]
  • [Cites] Science. 2002 Oct 18;298(5593):604-7 [12202684.001]
  • [Cites] Cognition. 2003 Mar;87(2):B69-77 [12590043.001]
  • [Cites] Neurology. 2003 May 27;60(10):1615-20 [12771251.001]
  • [Cites] Cognition. 2003 Nov;90(1):91-117 [14597271.001]
  • [Cites] Neuroimage. 2003 Nov;20 Suppl 1:S8-17 [14597292.001]
  • [Cites] J Int Neuropsychol Soc. 2003 Nov;9(7):1041-52 [14738285.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2004 Feb;75(2):213-20 [14742591.001]
  • [Cites] Eur J Neurosci. 2004 Jan;19(1):181-9 [14750976.001]
  • [Cites] Arch Clin Neuropsychol. 2004 Mar;19(2):203-14 [15010086.001]
  • [Cites] Ann Neurol. 2004 Apr;55(4):522-9 [15048891.001]
  • [Cites] Brain Lang. 2004 Jun;89(3):524-30 [15120543.001]
  • [Cites] Int J Lang Commun Disord. 2004 Jul-Sep;39(3):401-22 [15204448.001]
  • [Cites] Neurology. 1981 Oct;31(10):1333-5 [6125919.001]
  • [Cites] J Neuropathol Exp Neurol. 1985 Nov;44(6):559-77 [2932539.001]
  • [Cites] Cortex. 1986 Mar;22(1):11-32 [2940074.001]
  • [Cites] Neurology. 1988 Mar;38(3):341-7 [2964565.001]
  • [Cites] J Neurophysiol. 1989 Apr;61(4):814-32 [2723722.001]
  • [Cites] Brain Lang. 1989 Nov;37(4):628-42 [2479447.001]
  • [Cites] Acta Neurol Belg. 1990;90(4):207-17 [2124031.001]
  • [Cites] Neurology. 1991 Jul;41(7):1117-23 [1829794.001]
  • [Cites] AJNR Am J Neuroradiol. 1991 Nov-Dec;12(6):1217-22 [1763757.001]
  • [Cites] Neuroscience. 1995 Sep;68(2):273-85 [7477940.001]
  • [Cites] Mov Disord. 1996 Mar;11(2):136-42 [8684382.001]
  • [Cites] J Commun Disord. 1996 May-Jun;29(3):183-97 [8799853.001]
  • [Cites] Science. 1996 Dec 13;274(5294):1926-8 [8943209.001]
  • [Cites] Neuropsychology. 1997 Apr;11(2):272-81 [9110333.001]
  • [Cites] Science. 1997 Jul 18;277(5324):376-80 [9219696.001]
  • [Cites] Psychol Rev. 1998 Jan;105(1):158-73 [9450375.001]
  • [Cites] J Neurosci. 1998 Mar 1;18(5):1841-7 [9465008.001]
  • [Cites] J Neuropathol Exp Neurol. 1998 May;57(5):369-84 [9596408.001]
  • [Cites] Brain. 1998 Jul;121 ( Pt 7):1343-55 [9679785.001]
  • [Cites] Stroke. 1999 Jan;30(1):100-8 [9880396.001]
  • [Cites] Brain. 1999 Sep;122 ( Pt 9):1667-78 [10468506.001]
  • [Cites] Cereb Cortex. 2004 Dec;14(12):1302-9 [15166103.001]
  • [Cites] Trends Cogn Sci. 2005 Feb;9(2):83-9 [15668101.001]
  • [Cites] Neuroreport. 2005 Feb 8;16(2):111-5 [15671857.001]
  • [Cites] Brain. 2005 Mar;128(Pt 3):584-96 [15659423.001]
  • [Cites] Nature. 2005 Feb 24;433(7028):873-6 [15729344.001]
  • [Cites] Neuroimage. 2005 Apr 15;25(3):958-68 [15808996.001]
  • [Cites] Brain. 2005 May;128(Pt 5):1155-67 [15788544.001]
  • [Cites] Cognition. 2005 Sep;97(2):B25-34 [16226557.001]
  • [Cites] Clin Sci (Lond). 2006 Jan;110(1):73-88 [16336206.001]
  • (PMID = 18842608.001).
  • [ISSN] 1460-2156
  • [Journal-full-title] Brain : a journal of neurology
  • [ISO-abbreviation] Brain
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ HALMS345589; NLM/ PMC2773249
  •  go-up   go-down


7. Xu J, Bernuci MP, Lawson MS, Yeoman RR, Fisher TE, Zelinski MB, Stouffer RL: Survival, growth, and maturation of secondary follicles from prepubertal, young, and older adult rhesus monkeys during encapsulated three-dimensional culture: effects of gonadotropins and insulin. Reproduction; 2010 Nov;140(5):685-97
Hazardous Substances Data Bank. ALGIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival, growth, and maturation of secondary follicles from prepubertal, young, and older adult rhesus monkeys during encapsulated three-dimensional culture: effects of gonadotropins and insulin.
  • A three-dimensional culture system supports the development of primate preantral follicles to the antral stage with appreciable steroid production.
  • This study assessed i) whether in vitro developmental competence of follicles is age dependent, ii) the role of gonadotropins and insulin in supporting folliculogenesis, and iii) anti-Müllerian hormone (AMH) and vascular endothelial growth factor (VEGF) production by growing follicles.
  • Ovaries were obtained from prepubertal, young, and older adult rhesus macaques.

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. PROGESTERONE .
  • Hazardous Substances Data Bank. MENOTROPINS .
  • Hazardous Substances Data Bank. ALGINIC ACID .
  • Hazardous Substances Data Bank. CALCIUM ALGINATE .
  • Hazardous Substances Data Bank. POTASSIUM ALGINATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 1990 Apr;70(4):894-902 [2108185.001]
  • [Cites] J Anim Sci. 1991 Aug;69(8):3321-34 [1894569.001]
  • [Cites] Endocrinology. 1992 Jul;131(1):254-60 [1612003.001]
  • [Cites] J Endocrinol. 1992 Dec;135(3):589-95 [1487710.001]
  • [Cites] Biol Reprod. 1993 Feb;48(2):349-56 [8439624.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Nov;77(5):1411-8 [8077342.001]
  • [Cites] Endocr J. 1993 Dec;40(6):715-26 [7951542.001]
  • [Cites] Hum Reprod. 1994 Jul;9(7):1237-42 [7962424.001]
  • [Cites] Hum Reprod. 1995 Jul;10(7):1658-66 [8582957.001]
  • [Cites] Endocr Rev. 1996 Apr;17(2):121-55 [8706629.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Oct;81(10):3722-6 [8855829.001]
  • [Cites] Nat Genet. 1997 Feb;15(2):201-4 [9020850.001]
  • [Cites] Endocr Rev. 1997 Feb;18(1):71-106 [9034787.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jul;82(7):2135-42 [9215284.001]
  • [Cites] Gynecol Endocrinol. 1997 Dec;11(6):371-81 [9476086.001]
  • [Cites] Hum Reprod. 1998 May;13(5):1292-302 [9647562.001]
  • [Cites] J Reprod Fertil. 1998 May;113(1):19-26 [9713372.001]
  • [Cites] Biol Reprod. 1998 Dec;59(6):1445-53 [9828191.001]
  • [Cites] Maturitas. 1998 Oct 12;30(2):137-42 [9871908.001]
  • [Cites] Hum Reprod. 1999 Jun;14(6):1555-62 [10357975.001]
  • [Cites] Mol Cell Endocrinol. 2005 Apr 29;234(1-2):87-93 [15836957.001]
  • [Cites] Biol Reprod. 2005 Nov;73(5):942-50 [15987824.001]
  • [Cites] Rev Epidemiol Sante Publique. 2005 Nov;53 Spec No 2:2S37-45 [16471143.001]
  • [Cites] Reprod Biol Endocrinol. 2006;4:16 [16603089.001]
  • [Cites] Hum Reprod. 2006 Sep;21(9):2223-7 [16720622.001]
  • [Cites] Mol Endocrinol. 2006 Oct;20(10):2456-68 [16740654.001]
  • [Cites] Clin Chim Acta. 2007 Jan;375(1-2):162-4 [16860302.001]
  • [Cites] Endocrinology. 2007 May;148(5):2301-8 [17255205.001]
  • [Cites] Endocrinology. 2007 May;148(5):2273-81 [17317775.001]
  • [Cites] Zygote. 2007 May;15(2):173-82 [17462110.001]
  • [Cites] Hum Reprod. 2009 Sep;24(9):2264-75 [19520713.001]
  • [Cites] Biol Reprod. 2009 Sep;81(3):587-94 [19474063.001]
  • [Cites] Hum Reprod. 2009 Oct;24(10):2531-40 [19597190.001]
  • [Cites] Hum Reprod Update. 2010 Jan-Feb;16(1):39-50 [19752047.001]
  • [Cites] Fertil Steril. 2010 Mar 15;93(5):1421-9 [19243760.001]
  • [Cites] J Clin Endocrinol Metab. 2010 May;95(5):2306-15 [20200332.001]
  • [Cites] Mol Hum Reprod. 2007 Jun;13(6):361-71 [17416905.001]
  • [Cites] Tissue Eng. 2006 Oct;12(10):2739-46 [17518643.001]
  • [Cites] Soc Reprod Fertil Suppl. 2007;63:327-42 [17566282.001]
  • [Cites] Soc Reprod Fertil Suppl. 2007;63:531-8 [17566297.001]
  • [Cites] Biomaterials. 2007 Oct;28(30):4439-48 [17643486.001]
  • [Cites] Reproduction. 2008 Dec;136(6):703-15 [19074213.001]
  • [Cites] Biol Reprod. 2009 Mar;80(3):432-9 [19005169.001]
  • [Cites] Reprod Fertil Dev. 2009;21(5):679-87 [19486605.001]
  • [Cites] Theriogenology. 2009 Jul 15;72(2):243-50 [19362733.001]
  • [Cites] Biol Reprod. 2000 Jul;63(1):320-7 [10859274.001]
  • [Cites] Mol Hum Reprod. 2000 Aug;6(8):694-8 [10908278.001]
  • [Cites] Mol Cell Endocrinol. 2000 May 25;163(1-2):61-6 [10963875.001]
  • [Cites] Biol Reprod. 2001 Jan;64(1):293-8 [11133686.001]
  • [Cites] Baillieres Best Pract Res Clin Obstet Gynaecol. 2000 Dec;14(6):883-900 [11141339.001]
  • [Cites] Reproduction. 2001 May;121(5):647-53 [11427152.001]
  • [Cites] Reproduction. 2001 Dec;122(6):829-38 [11732978.001]
  • [Cites] Arch Med Res. 2001 Nov-Dec;32(6):567-75 [11750732.001]
  • [Cites] J Vet Med Sci. 2002 Sep;64(9):803-6 [12399605.001]
  • [Cites] Hum Reprod. 2002 Nov;17(11):2825-31 [12407033.001]
  • [Cites] Reproduction. 2002 Nov;124(5):601-9 [12416998.001]
  • [Cites] Mol Hum Reprod. 2004 Feb;10(2):77-83 [14742691.001]
  • [Cites] Endocrinology. 2004 Jun;145(6):2896-905 [14988387.001]
  • [Cites] Biol Reprod. 2004 Jul;71(1):282-90 [15028627.001]
  • [Cites] N Engl J Med. 1972 Dec 28;287(26):1313-7 [4344039.001]
  • [Cites] J Exp Zool. 1974 Oct;190(1):123-7 [4436619.001]
  • [Cites] J Reprod Fertil. 1975 Oct;45(1):83-90 [1195259.001]
  • [Cites] Am J Obstet Gynecol. 1976 Sep 1;126(1):91-4 [961752.001]
  • [Cites] Br J Obstet Gynaecol. 1979 May;86(5):354-63 [465383.001]
  • [Cites] Steroids. 1980 Jul;36(1):53-63 [7414656.001]
  • [Cites] Mol Cell Endocrinol. 1984 May;35(2-3):97-105 [6428947.001]
  • [Cites] Obstet Gynecol. 1984 Sep;64(3 Suppl):73S-80S [6382082.001]
  • (PMID = 20729335.001).
  • [ISSN] 1741-7899
  • [Journal-full-title] Reproduction (Cambridge, England)
  • [ISO-abbreviation] Reproduction
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / RL1 HD058294; United States / NICHD NIH HHS / HD / T32 HD007133-21; United States / NICHD NIH HHS / HD / RL1 HD058293; United States / NCRR NIH HHS / RR / P51 RR000163-51; United States / NICHD NIH HHS / HD / U54 HD018185-25; United States / NCRR NIH HHS / RR / P51 RR000163; United States / NICHD NIH HHS / HD / R01-HD058294; United States / NCRR NIH HHS / RR / RR024926-01; United States / NCRR NIH HHS / RR / RR00163; United States / FIC NIH HHS / TW / D43 TW000668-05; United States / NICHD NIH HHS / HD / U54-HD18185; United States / FIC NIH HHS / TW / D43 TW000668; United States / NICHD NIH HHS / HD / RL1 HD058293-05; United States / NICHD NIH HHS / HD / HD018185-25; United States / NIBIB NIH HHS / EB / PL1 EB008542-01; United States / NIBIB NIH HHS / EB / PL1 EB008542; United States / NCRR NIH HHS / RR / K01 RR000163; United States / NCRR NIH HHS / RR / UL1 RR024926; United States / NICHD NIH HHS / HD / T32 HD007133; United States / NCRR NIH HHS / RR / UL1 RR024926-01; United States / NICHD NIH HHS / HD / RL1 HD058294-01; United States / NIBIB NIH HHS / EB / EB008542-01; United States / NICHD NIH HHS / HD / RL1 HD058294-05; United States / FIC NIH HHS / TW / D43TW000668; United States / NICHD NIH HHS / HD / U54 HD018185; United States / NICHD NIH HHS / HD / HD07133; United States / NIBIB NIH HHS / EB / PL1-EB008542
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Alginates; 0 / Hexuronic Acids; 0 / Insulin; 0 / Vascular Endothelial Growth Factor A; 4G7DS2Q64Y / Progesterone; 4TI98Z838E / Estradiol; 80497-65-0 / Anti-Mullerian Hormone; 8A5D83Q4RW / Glucuronic Acid; 8C3Z4148WZ / alginic acid; 9002-68-0 / Follicle Stimulating Hormone
  • [Other-IDs] NLM/ NIHMS370551; NLM/ PMC3351200
  •  go-up   go-down


8. Homesley HD, Filiaci V, Gibbons SK, Long HJ, Cella D, Spirtos NM, Morris RT, DeGeest K, Lee R, Montag A: A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study. Gynecol Oncol; 2009 Mar;112(3):543-52
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study.
  • OBJECTIVES: After surgical debulking and volume-directed irradiation of the pelvis/para-aortic lymph nodes, treatment was randomized to compare recurrence-free survival (RFS) and toxicity between two chemotherapy regimens for the treatment of women with advanced stage endometrial carcinoma.
  • Accrual closed to Stage IV patients in June, 2003.
  • The hazard of recurrence or death relative to the CD arm stratified by stage is 0.90 (95% CI is 0.69 to 1.17, p=0.21, one-tail).
  • However, in subgroup analysis, CDP was associated with a 50% reduction in the risk of recurrence or death among patients with gross residual disease (95% CI: 0.26 to 0.92).
  • Stage, residual disease, histology/grade, positive para-aortic node and cytology, pelvic metastases and age were significantly associated with RFS.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19108877.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / U10 CA027469; United States / NCI NIH HHS / CA / U10 CA101165-04; United States / NCI NIH HHS / CA / U10 CA037517; United States / NCI NIH HHS / CA / U10 CA027469-22; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 80168379AG / Doxorubicin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ NIHMS102171; NLM/ PMC4459781
  •  go-up   go-down


9. Chambon JP, Alarcon B, N'Guyen HD, Gaillard R, Pagniez D, Dumont A: [Results of infrainguinal revascularization in patients with end-stage renal disease]. Ann Chir; 2005 Jan;130(1):26-31
MedlinePlus Health Information. consumer health - Kidney Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of infrainguinal revascularization in patients with end-stage renal disease].
  • OBJECTIVES: The aim of this retrospective study was to evaluate the efficacy of bypass in patients with endstage renal disease (ESRD) and to determine predictive factors and precise bypass indications.
  • METHOD: Forty one patients with ESRD underwent 50 bypass, 6 limbs were stage II and 44 stage III or IV according to Leriche and Fontaine classification.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Inguinal Canal / blood supply. Inguinal Canal / surgery. Kidney / blood supply. Male. Middle Aged. Morbidity. Prognosis. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15664373.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


10. Lamm BM, Gottlieb HD, Paley D: A two-stage percutaneous approach to charcot diabetic foot reconstruction. J Foot Ankle Surg; 2010 Nov-Dec;49(6):517-22
MedlinePlus Health Information. consumer health - Diabetic Foot.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A two-stage percutaneous approach to charcot diabetic foot reconstruction.
  • Feet were operated on at various stages of Charcot deformity: Eichenholtz stage I (1 foot), Eichenholtz stage II (6 feet), and Eichenholtz stage III (4 feet).
  • [MeSH-minor] Achilles Tendon / surgery. Adult. Aged. Equinus Deformity / surgery. Female. Fluoroscopy. Foot Bones / surgery. Foot Joints / radiography. Foot Joints / surgery. Humans. Male. Middle Aged. Muscle, Skeletal / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American College of Foot and Ankle Surgeons. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20864361.001).
  • [ISSN] 1542-2224
  • [Journal-full-title] The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons
  • [ISO-abbreviation] J Foot Ankle Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Möbus V, Wandt H, Frickhofen N, Bengala C, Champion K, Kimmig R, Ostermann H, Hinke A, Ledermann JA, AGO-Ovar/AIO, EBMT: Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT. J Clin Oncol; 2007 Sep 20;25(27):4187-93
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT.
  • PATIENTS AND METHODS: One hundred forty-nine patients with untreated ovarian cancer were randomly assigned after debulking surgery to receive standard combination chemotherapy or sequential high-dose (HD) treatment with two cycles of cyclophosphamide and paclitaxel followed by three cycles of HD carboplatin and paclitaxel with PBSC support.
  • HD melphalan was added to the final cycle.
  • The median age was 50 years (range, 20 to 65 years) and International Federation of Gynecology and Obstetrics stage was IIb/IIc in 4%, III in 78%, and IV in 17%.
  • RESULTS: Seventy-six percent of patients received all five cycles in the HD arm and the main toxicities were neuro-/ototoxicity, gastrointestinal toxicity, and infection and one death from hemorrhagic shock.
  • After a median follow-up of 38 months, the progression-free survival was 20.5 months in the standard arm and 29.6 months in the HD arm (hazard ratio [HR], 0.84; 95% CI, 0.56 to 1.26; P, .40).
  • Median overall survival (OS) was 62.8 months in the standard arm and 54.4 months in the HD arm (HR, 1.17; 95% CI, 0.71 to 1.94; P, .54).
  • CONCLUSION: This is the first randomized trial comparing sequential HD versus standard dose chemotherapy in first-line treatment of patients with advanced ovarian cancer.
  • We observed no statistically significant difference in progression-free survival or OS and conclude that HD chemotherapy does not appear to be superior to conventional dose chemotherapy.
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Melphalan / administration & dosage. Middle Aged. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2007 Sep 20;25(27):4157-8 [17698802.001]
  • (PMID = 17698804.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 8N3DW7272P / Cyclophosphamide; P88XT4IS4D / Paclitaxel; Q41OR9510P / Melphalan
  •  go-up   go-down


12. Siriwardana HD, Pathirana A: Adenocarcinoma of the stomach in a tertiary care hospital in Sri Lanka. Ceylon Med J; 2007 Jun;52(2):53-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our objective was to describe the location of the tumour, stage at presentation, resectability and survival in a cohort of patients with adenocarcinoma of the stomach, presenting to a tertiary referral centre.
  • 93% had Stage III or IV disease at presentation.
  • CONCLUSION: All our patients presented with advanced gastric cancer and the majority had unresectable disease.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Factors. Sri Lanka / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17691560.001).
  • [ISSN] 0009-0875
  • [Journal-full-title] The Ceylon medical journal
  • [ISO-abbreviation] Ceylon Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Sri Lanka
  •  go-up   go-down


13. Moalli PA, Shand SH, Zyczynski HM, Gordy SC, Meyn LA: Remodeling of vaginal connective tissue in patients with prolapse. Obstet Gynecol; 2005 Nov;106(5 Pt 1):953-63
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tissue of 15 premenopausal women with less than stage II prolapse (controls) was compared with that of 62 women with prolapse divided according to their menopausal status.
  • Scanning confocal microscopic analysis of fluorescent micrographs was used to quantitate collagen subtypes I, III, and V.
  • Median values were compared using Mann-Whitney U or Kruskal-Wallis tests, where appropriate RESULTS: Vaginal collagen fibers are arranged in a whorled pattern, with collagen III as the predominant fibrillar collagen.
  • The amount of total collagen in the vagina was increased in women with prolapse relative to women without prolapse (P = .054) primarily due to increased expression of collagen III (P = .031).
  • There was no difference in the expression of proMMP-2, active MMP-2, or proMMP-9; however, active MMP-9 was increased in patients with prolapse (P = .030) CONCLUSION: The increase in collagen III and active MMP-9 expression in the vaginal tissues of patients with prolapse suggests that this tissue is actively remodeling under the biomechanical stresses associated with prolapse.
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Estrogen Replacement Therapy. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Pelvic Support Problems.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16260512.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / R01 HD 045590
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fibrillar Collagens; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


14. Hentrich M, Maretta L, Chow KU, Bogner JR, Schürmann D, Neuhoff P, Jäger H, Reichelt D, Vogel M, Ruhnke M, Oette M, Weiss R, Rockstroh J, Arasteh K, Mitrou P: Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study. Ann Oncol; 2006 Jun;17(6):914-9
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study.
  • BACKGROUND: The purpose of the study was to evaluate the outcome of Hodgkin's disease (HD) in patients infected with the human immunodeficiency virus (HIV) with respect to the use of highly active antiretroviral therapy (HAART).
  • MATERIALS AND METHODS: This cohort study included patients with HIV-HD diagnosed from June 1984 to February 2004.
  • RESULTS: Of 66 patients with HIV-HD, 47 (71%) presented with stage III/IV disease and 38 patients (58%) with an AIDS-defining illness.
  • Three-year mortality was significantly higher in patients without complete remission (HR 4.40, CI 1.77-10.99), with stage III/IV HD (HR 4.64, CI 1.31-16.49) and with CD4 cells <200/microl (HR 2.69, CI 0.99-7.33).
  • CONCLUSIONS: Use of HAART significantly improved the overall survival in patients with HIV-HD.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16565210.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


15. Carl HD, Schraml A, Swoboda B, Hohenberger G: Synovectomy of the hip in patients with juvenile rheumatoid arthritis. J Bone Joint Surg Am; 2007 Sep;89(9):1986-92
MedlinePlus Health Information. consumer health - Juvenile Arthritis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fifty-five hips (82%) had radiographic changes that were stage III or higher according to the system of Larsen et al.
  • [MeSH-minor] Adolescent. Adult. Arthroplasty, Replacement, Hip. Child. Curettage. Debridement. Female. Follow-Up Studies. Hematoma / etiology. Humans. Joint Capsule / surgery. Male. Pain Measurement. Postoperative Complications. Range of Motion, Articular / physiology. Survival Rate. Walking / physiology. Weight-Bearing / physiology


16. Meeske KA, Sullivan-Halley J, Smith AW, McTiernan A, Baumgartner KB, Harlan LC, Bernstein L: Risk factors for arm lymphedema following breast cancer diagnosis in Black women and White women. Breast Cancer Res Treat; 2009 Jan;113(2):383-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Methods 494 women (271 White and 223 Black) with in situ to Stage III-A primary breast cancer completed a baseline interview within 18 months of diagnosis.
  • [MeSH-minor] Adult. Age Factors. Antineoplastic Agents / therapeutic use. Arm. Cohort Studies. Combined Modality Therapy. Comorbidity. Contraceptives, Oral / adverse effects. Female. Follow-Up Studies. Humans. Hypertension / epidemiology. Infection / epidemiology. Lymph Node Excision / adverse effects. Middle Aged. Obesity / epidemiology. Radiotherapy / adverse effects. Risk Factors

  • Genetic Alliance. consumer health - Lymphedema.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - African American Health.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lymphedema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18297429.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 116848; United States / NICHD NIH HHS / HD / N01 HD 3-3175; United States / NCI NIH HHS / PC / N01-PC-35139
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Contraceptives, Oral
  •  go-up   go-down


17. Potapov EV, Hennig F, Wagner FD, Volk HD, Sodian R, Hausmann H, Lehmkuhl HB, Hetzer R: Natriuretic peptides and E-selectin as predictors of acute deterioration in patients with inotrope-dependent heart failure. Eur J Cardiothorac Surg; 2005 May;27(5):899-905
Hazardous Substances Data Bank. DOPAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: In patients with inotrope-dependent end-stage heart failure the timely application of the most suitable treatment, i.e. heart transplantation, implantation of a ventricular assist device or conservative treatment, is a key issue for therapeutic success.
  • METHODS: Seventy-six inotrope-dependent patients with end-stage heart failure were enrolled.
  • The patients were retrospectively divided into groups with regard to the following end-points: Group I-deterioration into cardiogenic shock after an initially stable clinical course (n=26); Group II-stable clinical course without deterioration into cardiogenic (n=41); Group III-weaning from inotropic support (n=9).
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers / blood. C-Reactive Protein / analysis. Dobutamine / administration & dosage. Dobutamine / therapeutic use. Dopamine / administration & dosage. Dopamine / therapeutic use. Drug Administration Schedule. Drug Therapy, Combination. Enoximone / administration & dosage. Enoximone / therapeutic use. Epidemiologic Methods. Epinephrine / administration & dosage. Epinephrine / therapeutic use. Female. Humans. Male. Middle Aged. Natriuretic Peptide, Brain / blood. Nerve Tissue Proteins / blood. Norepinephrine / administration & dosage. Norepinephrine / therapeutic use. Peptide Fragments / blood. Prognosis. Shock, Cardiogenic / blood. Shock, Cardiogenic / drug therapy

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Norepinephrine .
  • Hazardous Substances Data Bank. EPINEPHRINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15848333.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / E-Selectin; 0 / Natriuretic Peptides; 0 / Nerve Tissue Proteins; 0 / Peptide Fragments; 0 / pro-brain natriuretic peptide (1-76); 114471-18-0 / Natriuretic Peptide, Brain; 3S12J47372 / Dobutamine; 9007-41-4 / C-Reactive Protein; C7Z4ITI7L7 / Enoximone; VTD58H1Z2X / Dopamine; X4W3ENH1CV / Norepinephrine; YKH834O4BH / Epinephrine
  •  go-up   go-down


18. Stanton CA, Papandonatos G, Lloyd-Richardson EE, Niaura R: Consistency of self-reported smoking over a 6-year interval from adolescence to young adulthood. Addiction; 2007 Nov;102(11):1831-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN: A total of 12 985 respondents to cigarette smoking questions during in-home interviews at waves I and III (6 years apart) of the National Longitudinal Study of Adolescent Health (Add Health).
  • FINDINGS: Stage-specific results indicated that recanting is higher when the earlier smoking was less frequent/intense.

  • MedlinePlus Health Information. consumer health - Smoking.
  • MedlinePlus Health Information. consumer health - Smoking and Youth.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Public Health. 1997 Jan;87(1):56-61 [9065227.001]
  • [Cites] Nicotine Tob Res. 2004 Feb;6(1):19-25 [14982684.001]
  • [Cites] Am J Public Health. 1998 Feb;88(2):309-10 [9491034.001]
  • [Cites] Ann Epidemiol. 1998 Aug;8(6):393-401 [9708875.001]
  • [Cites] Subst Use Misuse. 1999 Jan;34(2):269-95 [10069753.001]
  • [Cites] Am J Public Health. 1999 Oct;89(10):1522-8 [10511834.001]
  • [Cites] Addict Behav. 2005 Jan;30(1):175-81 [15561458.001]
  • [Cites] Addiction. 2005 Feb;100(2):143-4 [15679741.001]
  • [Cites] Addiction. 2005 Feb;100(2):189-96 [15679748.001]
  • [Cites] Soc Sci Med. 2005 May;60(9):2073-84 [15743655.001]
  • [Cites] Prev Med. 2005 Aug;41(2):646-50 [15917064.001]
  • [Cites] Am J Epidemiol. 2005 Sep 1;162(5):461-70 [16076832.001]
  • [Cites] Addict Behav. 2006 Jan;31(1):133-6 [15922514.001]
  • [Cites] Drug Alcohol Depend. 2000 Jul 1;60(1):19-27 [10821986.001]
  • [Cites] Addiction. 2001 Aug;96(8):1187-98 [11487424.001]
  • [Cites] Am J Public Health. 2006 Feb;96(2):299-308 [16380569.001]
  • [Cites] J Consult Clin Psychol. 2002 Aug;70(4):998-1009 [12182283.001]
  • [Cites] J Drug Educ. 2002;32(4):271-86 [12556133.001]
  • [Cites] Drug Alcohol Depend. 2003 Jun 5;70(3):241-53 [12757962.001]
  • [Cites] Addiction. 2003 Sep;98(9):1307-13 [12930218.001]
  • [Cites] Psychol Addict Behav. 2003 Sep;17(3):211-8 [14498815.001]
  • [Cites] NIDA Res Monogr. 1997;167:59-80 [9243557.001]
  • (PMID = 17784897.001).
  • [ISSN] 0965-2140
  • [Journal-full-title] Addiction (Abingdon, England)
  • [ISO-abbreviation] Addiction
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA095623-05; United States / NICHD NIH HHS / HD / P01 HD031921; United States / NHLBI NIH HHS / HL / K23 HL069987; United States / NCI NIH HHS / CA / P50 CA084719-06; United States / NCI NIH HHS / CA / P50 CA084719; United States / NCI NIH HHS / CA / K07 CA095623-05; United States / NCI NIH HHS / CA / K07 CA095623; United States / NICHD NIH HHS / HD / P01-HD31921; United States / NCI NIH HHS / CA / CA084719-06; United States / NCI NIH HHS / CA / K07CA95623; United States / NHLBI NIH HHS / HL / K23HL069987
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS176731; NLM/ PMC3500030
  •  go-up   go-down


19. Busch M, Göbert A, Franke S, Ott U, Gerth J, Müller A, Stein G, Bitsch R, Wolf G: Vitamin B6 metabolism in chronic kidney disease--relation to transsulfuration, advanced glycation and cardiovascular disease. Nephron Clin Pract; 2010;114(1):c38-46
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vitamin B6 metabolism in chronic kidney disease--relation to transsulfuration, advanced glycation and cardiovascular disease.
  • BACKGROUND: Vitamin deficiency is common in chronic kidney disease (CKD).
  • METHODS: In 48 CKD patients at stage 2-4, 72 hemodialysis patients (HD), 38 renal transplant recipients (RTR) and 141 healthy controls (mean age 58 +/- 13, 61 +/- 12, 50 +/- 12 and 54 +/- 16 years, respectively), plasma and red blood cell (RBC) concentrations of pyridoxal-5'-phosphate (PLP), pyridoxal (PL), 4-pyridoxic acid (PA), pyridoxamine-5'-phosphate (PMP) and of the AGE pentosidine were measured by high-performance liquid chromatography, N(epsilon)-(carboxymethyl)lysine and imidazolone by an ELISA, and total homocysteine and cystathionine by gas chromatography-mass spectrometry.
  • RESULTS: Despite routine low-dose vitamin supplementation in HD, plasma PLP was decreased in HD (79 +/- 69 nmol/l) compared with CKD stage 2-4 patients (497 +/- 944 nmol/l), RTR (416 +/- 604 nmol/l) and controls (159 +/- 230 nmol/l; p < 0.001).
  • Plasma PA was significantly increased in HD (11,667 +/- 17,871 nmol/l) in comparison with CKD stage 2-4 (435 +/- 441 nmol/l), RTR (583 +/- 668 nmol/l) and controls (46 +/- 49 nmol/l; p < 0.001).
  • B(6) forms were significantly affected by renal function (R = 0.792, p < 0.001 for CKD stage 2-4).
  • Relationships between B(6) forms and AGE (RBC-PMP with pentosidine in CKD stage 2-4: R = -0.351, p < 0.05) were found.
  • CONCLUSION: HD patients showed a deficiency in PLP in plasma but not in RBC.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cardiovascular Diseases / epidemiology. Erythrocytes / chemistry. Female. Glycosylation End Products, Advanced / analysis. Humans. Male. Middle Aged. Pyridoxal / blood. Pyridoxal Phosphate / blood. Pyridoxamine / blood. Pyridoxic Acid / blood

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Chronic Kidney Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19816042.001).
  • [ISSN] 1660-2110
  • [Journal-full-title] Nephron. Clinical practice
  • [ISO-abbreviation] Nephron Clin Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Glycosylation End Products, Advanced; 3THM379K8A / Pyridoxal; 5K18793O8D / Pyridoxic Acid; 5V5IOJ8338 / Pyridoxal Phosphate; 6466NM3W93 / Pyridoxamine; 8059-24-3 / Vitamin B 6
  •  go-up   go-down


20. El-Shafey EM, El-Nagar GF, Selim MF, El-Sorogy HA, Sabry AA: Is there a role for endothelin-1 in the hemodynamic changes during hemodialysis? Clin Exp Nephrol; 2008 Oct;12(5):370-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The etiology of hemodialysis (HD)-induced hypotension and hypertension remains speculative.
  • We examined the possible role of intradialytic changes of ET-1 in the pathogenesis of hypotension and rebound hypertension during HD.
  • METHODS: The present study included 45 patients with end-stage renal disease (ESRD) on regular HD.
  • They were divided according to their hemodynamic status during HD into three groups (group I had stable intradialytic hemodynamics, group II had dialysis-induced hypotension, and group III had rebound hypertension during HD).
  • Pulse and blood pressure were monitored before, during (every half hour), and after HD session.
  • ET-1 level was measured at the beginning, middle, and end of HD.
  • RESULTS: Pre-dialysis levels of ET-1 were significantly higher in dialysis patients compared to the controls (P < 0.001); however, they were comparable in the three HD groups.
  • The post-dialysis ET-1 level was not changed significantly in group I compared with predialysis values (14.49 +/- 2.04 vs. 14.33 +/- 2.23 pg/ml; P = NS), while the ET-1 concentration decreased significantly in group II and increased in group III in comparison to predialysis values (8.56 +/- 1.44 vs. 11.75 +/- 2.51; 16.39 +/- 3.12 vs. 11.93 +/- 2.11 pg/ml, respectively; P < 0.001).
  • CONCLUSION: Altered ET-1 levels may be involved in the pathogenesis of rebound hypertension and hypotension during HD.
  • [MeSH-minor] Adult. Blood Pressure / physiology. Case-Control Studies. Egypt. Female. Heart Rate / physiology. Humans. Male. Middle Aged. Prospective Studies


21. Wolf RC, Vasic N, Schönfeldt-Lecuona C, Ecker D, Landwehrmeyer GB: Cortical dysfunction in patients with Huntington's disease during working memory performance. Hum Brain Mapp; 2009 Jan;30(1):327-39
SciCrunch. NeuroSynth: Data: Activation Foci .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cortical dysfunction in patients with Huntington's disease during working memory performance.
  • Previous functional neuroimaging studies on executive function suggested multiple functionally aberrant cortical regions in patients with Huntington's disease (HD).
  • The objective of this study was to investigate the functional neuroanatomy of WM in HD patients.
  • We used event-related functional magnetic resonance imaging and a parametric verbal WM task to investigate cerebral function during WM performance in 16 healthy control subjects and 12 mild to moderate stage HD patients.
  • We found that HD patients were slower and less accurate than healthy controls across all WM load levels.
  • In addition, HD patients showed lower activation in the left dorso- and ventrolateral prefrontal cortex, the left inferior parietal cortex, the left putamen, and the right cerebellum at high WM load levels only.
  • These findings demonstrate that WM-related functional abnormalities in HD patients involve distinct WM network nodes associated with cognitive control and subvocal rehearsal.
  • Moreover, aberrant cortical function in HD patients may occur in brain regions, which are relatively well preserved in terms of brain atrophy.
  • [MeSH-major] Atrophy / physiopathology. Cerebral Cortex / physiopathology. Cognition Disorders / physiopathology. Huntington Disease / physiopathology. Memory Disorders / physiopathology
  • [MeSH-minor] Adult. Brain Mapping. Cerebellum / pathology. Cerebellum / physiopathology. Corpus Striatum / pathology. Corpus Striatum / physiopathology. Disability Evaluation. Disease Progression. Female. Functional Laterality / physiology. Humans. Magnetic Resonance Imaging. Male. Memory, Short-Term / physiology. Middle Aged. Nerve Net / pathology. Nerve Net / physiopathology. Neuropsychological Tests. Predictive Value of Tests. Thalamus / pathology. Thalamus / physiopathology

  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • MedlinePlus Health Information. consumer health - Memory.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18172852.001).
  • [ISSN] 1097-0193
  • [Journal-full-title] Human brain mapping
  • [ISO-abbreviation] Hum Brain Mapp
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


22. Handa VL, Cundiff G, Chang HH, Helzlsouer KJ: Female sexual function and pelvic floor disorders. Obstet Gynecol; 2008 May;111(5):1045-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The study population included 301 adult women seeking outpatient gynecologic and urogynecologic care.
  • Stage III-IV prolapse was significantly associated with infrequent orgasm (P=.02), but other sexual complaints were not more common with increasing prolapse stage.

  • MedlinePlus Health Information. consumer health - Pelvic Support Problems.
  • MedlinePlus Health Information. consumer health - Sexual Problems in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Fertil Steril. 2002 Apr;77 Suppl 4:S42-8 [12007901.001]
  • [Cites] Obstet Gynecol. 2002 Feb;99(2):281-9 [11814510.001]
  • [Cites] Am J Obstet Gynecol. 2004 Sep;191(3):751-6 [15467535.001]
  • [Cites] Obstet Gynecol. 1995 Apr;85(4):483-7 [7898820.001]
  • [Cites] Med Care. 1996 Mar;34(3):220-33 [8628042.001]
  • [Cites] Am J Obstet Gynecol. 1996 Jul;175(1):10-7 [8694033.001]
  • [Cites] Int J Epidemiol. 1997 Dec;26(6):1323-33 [9447413.001]
  • [Cites] Am J Obstet Gynecol. 2005 Jul;193(1):103-13 [16021067.001]
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 2006 Jan;17(1):14-7 [15971004.001]
  • [Cites] J Sex Med. 2004 Jul;1(1):40-8 [16422982.001]
  • [Cites] Am J Obstet Gynecol. 2006 Nov;195(5):e1-4 [17074540.001]
  • [Cites] Obstet Gynecol. 2007 Apr;109(4):831-40 [17400843.001]
  • [Cites] Climacteric. 2007 Apr;10(2):132-42 [17453861.001]
  • [Cites] Am J Obstet Gynecol. 2007 Jul;197(1):88.e1-6 [17618771.001]
  • [Cites] Am J Obstet Gynecol. 2007 Jul;197(1):101.e1-6 [17618777.001]
  • [Cites] Cochrane Database Syst Rev. 2007;(3):CD004014 [17636742.001]
  • [Cites] Am J Obstet Gynecol. 2007 Dec;197(6):629.e1-6 [18060957.001]
  • [Cites] J Sex Marital Ther. 2002 Oct-Dec;28(5):389-97 [12378841.001]
  • [Cites] J Sex Marital Ther. 2001 Jul-Sep;27(4):339-51 [11441518.001]
  • [CommentIn] Obstet Gynecol. 2008 May;111(5):1037-8 [18448731.001]
  • (PMID = 18448734.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / K23 HD045806; United States / NICHD NIH HHS / HD / K23 HD045806-04; United States / NICHD NIH HHS / HD / K23HD045806
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS114870; NLM/ PMC2746737
  •  go-up   go-down


23. Mehta S, Giovannucci E, Mugusi FM, Spiegelman D, Aboud S, Hertzmark E, Msamanga GI, Hunter D, Fawzi WW: Vitamin D status of HIV-infected women and its association with HIV disease progression, anemia, and mortality. PLoS One; 2010 Jan 19;5(1):e8770
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vitamin D status of HIV-infected women and its association with HIV disease progression, anemia, and mortality.
  • BACKGROUND: Vitamin D has a potential role in slowing HIV disease progression and preventing mortality based on its extensive involvement in the immune system; however, this relationship has not been examined in large studies or in resource-limited settings.
  • Women were followed up for a median of 69.5 months, and information on hemoglobin levels, HIV disease progression, and mortality was recorded.
  • CONCLUSIONS/SIGNIFICANCE: Low vitamin D status (serum 25-hydroxyvitamin D<32 ng/mL) was significantly associated with progression to WHO HIV disease stage III or greater in multivariate models (incidence rate ratio [RR]: 1.25; 95% confidence intervals [CI]: 1.05, 1.50).
  • Vitamin D status had a protective association with HIV disease progression, all-cause mortality, and development of anemia during follow-up in HIV-infected women.

  • Genetic Alliance. consumer health - Anemia.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - Infections and Pregnancy.
  • MedlinePlus Health Information. consumer health - Vitamin D.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Soc Trans. 1982 Jun;10(3):147-58 [7049788.001]
  • [Cites] N Engl J Med. 2004 Jul 1;351(1):23-32 [15229304.001]
  • [Cites] Arch Dis Child. 1986 Sep;61(9):843-8 [3767413.001]
  • [Cites] J Pediatr. 1989 Feb;114(2):213-7 [2536807.001]
  • [Cites] Am J Public Health. 1989 Mar;79(3):340-9 [2916724.001]
  • [Cites] Stat Med. 1989 May;8(5):551-61 [2657958.001]
  • [Cites] Immunol Lett. 1989 Oct;22(4):307-11 [2697687.001]
  • [Cites] Blood. 1990 Jul 1;76(1):189-97 [2364169.001]
  • [Cites] Biochem Biophys Res Commun. 1991 Apr 30;176(2):852-9 [1673842.001]
  • [Cites] Am J Clin Nutr. 1992 Sep;56(3):533-6 [1503065.001]
  • [Cites] AIDS. 1993 May;7(5):711-8 [8100422.001]
  • [Cites] J Infect Dis. 1994 Apr;169(4):889-93 [7907645.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Dec;79(6):1701-5 [7989478.001]
  • [Cites] BMJ. 1999 Jan 2;318(7175):28 [9872879.001]
  • [Cites] Control Clin Trials. 1999 Feb;20(1):75-90 [10027501.001]
  • [Cites] J Nutr. 2005 Feb;135(2):317-22 [15671234.001]
  • [Cites] Science. 2006 Mar 24;311(5768):1770-3 [16497887.001]
  • [Cites] Nutr Rev. 2006 May;64(5 Pt 1):226-33 [16770943.001]
  • [Cites] J Nutr. 2007 Feb;137(2):447-52 [17237325.001]
  • [Cites] J Immunol. 2007 Aug 15;179(4):2060-3 [17675463.001]
  • [Cites] Stat Med. 2007 Sep 10;26(20):3735-52 [17538974.001]
  • [Cites] Ann N Y Acad Sci. 2007 Nov;1117:94-105 [17656563.001]
  • [Cites] N Engl J Med. 2008 Mar 13;358(11):1089-92 [18337598.001]
  • [Cites] J Infect. 2003 May;46(4):221-7 [12799147.001]
  • [Cites] J Clin Endocrinol Metab. 1983 Dec;57(6):1308-10 [6313738.001]
  • (PMID = 20098738.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / FIC NIH HHS / TW / D43 TW000004; United States / NICHD NIH HHS / HD / R01 HD032257; United States / FIC NIH HHS / TW / D43 TW00004; United States / PHS HHS / / R01 32257
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 1406-16-2 / Vitamin D
  • [Other-IDs] NLM/ PMC2808247
  •  go-up   go-down


24. Su HI, Sammel MD, Green J, Velders L, Stankiewicz C, Matro J, Freeman EW, Gracia CR, DeMichele A: Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors. Cancer; 2010 Feb 1;116(3):592-9
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Breast cancer patients (n = 127) with American Joint Committee on Cancer stage I to III disease who were premenopausal at diagnosis were enrolled postchemotherapy and observed.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Premature Ovarian Failure.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 American Cancer Society.
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5307-14 [14602766.001]
  • [Cites] Hum Reprod. 2003 Nov;18(11):2368-74 [14585889.001]
  • [Cites] Cancer. 1978 Jun;41(6):2084-7 [418867.001]
  • [Cites] Cancer Res. 1980 Nov;40(11):4043-7 [6451282.001]
  • [Cites] NCI Monogr. 1986;(1):105-9 [3534581.001]
  • [Cites] Cancer Res. 1987 Jan 15;47(2):624-30 [3098415.001]
  • [Cites] Am J Obstet Gynecol. 1992 Mar;166(3):788-93 [1550144.001]
  • [Cites] Clin Endocrinol (Oxf). 1994 Dec;41(6):771-7 [7889613.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1718-29 [8622093.001]
  • [Cites] Menopause. 2004 Nov-Dec;11(6 Pt 1):601-6 [15545787.001]
  • [Cites] Hum Reprod Update. 2005 Jan-Feb;11(1):69-89 [15569700.001]
  • [Cites] Fertil Steril. 2005 Feb;83(2):383-92 [15705379.001]
  • [Cites] Menopause. 2005 Mar;12(2):128-35 [15772558.001]
  • [Cites] Hum Reprod. 2005 Apr;20(4):923-7 [15640257.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2444-7 [16735701.001]
  • [Cites] Hum Reprod. 2006 Oct;21(10):2583-92 [16820385.001]
  • [Cites] Hum Reprod Update. 2006 Nov-Dec;12(6):685-718 [16891297.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5769-79 [17130515.001]
  • [Cites] Fertil Steril. 2007 Jan;87(1):101-6 [17109858.001]
  • [Cites] Br J Cancer. 2007 Jun 18;96(12):1808-16 [17533402.001]
  • [Cites] Hum Reprod Update. 2007 Nov-Dec;13(6):559-65 [17630397.001]
  • [Cites] Cancer Invest. 2008 Apr-May;26(3):286-95 [18317970.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Jun;93(6):2129-34 [18334591.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Sep;93(9):3478-83 [18593767.001]
  • [Cites] Cancer. 2008 Nov 1;113(9):2385-97 [18819158.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2365-70 [10561298.001]
  • [Cites] Eur J Cancer. 2000 Jan;36(1):43-8 [10741293.001]
  • [Cites] Climacteric. 2001 Dec;4(4):267-72 [11770182.001]
  • [Cites] Fertil Steril. 2002 Feb;77(2):357-62 [11821097.001]
  • [Cites] Breast Cancer Res Treat. 2003 Nov;82(2):103-11 [14692654.001]
  • (PMID = 19918920.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / R01 AG012745-14; United States / NICHD NIH HHS / HD / HD007440-12; United States / NICHD NIH HHS / HD / T32 HD007440; United States / NIA NIH HHS / AG / AG012745-14; United States / NICHD NIH HHS / HD / T32 HD007440-12; United States / NIA NIH HHS / AG / R01 AG012745; United States / NICHD NIH HHS / HD / 5-T32-HD007400-12
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers; 0 / inhibin B; 094ZI81Y45 / Tamoxifen; 57285-09-3 / Inhibins; 80497-65-0 / Anti-Mullerian Hormone; 9002-68-0 / Follicle Stimulating Hormone
  • [Other-IDs] NLM/ NIHMS153276; NLM/ PMC2815049
  •  go-up   go-down


25. Renedo RJ, Sousa MM, Pérez SF, Zabalbeascoa JR, Carro LP: Avascular necrosis of the femoral head in patients with Hodgkin's disease. Hip Int; 2010 Oct-Dec;20(4):473-81
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Avascular necrosis of the femoral head in patients with Hodgkin's disease.
  • Avascular necrosis of the femoral head (ANFH) is a rare complication that may occur in patients diagnosed with Hodgkin's Disease (HD), as a result of treatment.
  • A review was made of 315 cases of HD treated with systemic chemotherapy associated with high doses of steroids and radiation therapy and 18 patients (5.71%) were found to have developed ANFH during treatment.
  • In 8 cases (44.44%) forage associated with IES was performed as the initial treatment option and 6 of these cases were found to be in Ficat stage II (75%), 1 was found to be in stage III (12.55%) and another in stage IV (12.5%).
  • In 2 cases, the central decompression technique was used (Simple Forage); both were in Ficat stage II.
  • In the other 8 cases, a total hip arthroplasty (THA) was chosen as the initial treatment option, with 3 of these patients in Ficat stage III and 5 in Ficat stage IV.
  • We observed that treatment with Forage + IES was better than simple Forage in stages below III in patients with Hodgkin's Disease.
  • We considered that in Ficat stage III and IV arthroplasty (THA) was the better option.
  • [MeSH-major] Femur Head Necrosis / pathology. Hodgkin Disease / pathology
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Arthroplasty, Replacement, Hip. Decompression, Surgical. Electric Stimulation Therapy. Female. Glucocorticoids / adverse effects. Humans. Male. Middle Aged. Prednisone / adverse effects. Radiotherapy, Adjuvant. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21157752.001).
  • [ISSN] 1724-6067
  • [Journal-full-title] Hip international : the journal of clinical and experimental research on hip pathology and therapy
  • [ISO-abbreviation] Hip Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glucocorticoids; VB0R961HZT / Prednisone
  •  go-up   go-down


26. Sun XF, Zhen ZJ, Liu DG, Xia Y, Xiang XJ, Chen XQ, Ling JY, Zheng L, Luo WB, Lin H, He YJ, Guan ZZ: [Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents]. Ai Zheng; 2007 Dec;26(12):1339-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents].
  • BACKGROUND & OBJECTIVE: Burkitt's lymphoma is an aggressive non-Hodgkin's lymphoma (NHL) and often involves bone marrow and central nerve system.
  • The efficacy of CHOP regimen on Burkitt's lymphoma is poor.
  • This study was to evaluate the efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in children and adolescents, and observe the survival status.
  • 2006, 31 untreated Burkitt's lymphoma patients aged less than 20 were enrolled.
  • According to St Jude staging system, 1 (3.2%) was at stage I, 6 (19.4%) at stage II, 8 (25.8%) at stage III, 16 (51.6%) at stage IV; 24 (77.4%) were at stage III/IV.
  • According to clinical stage, lactate dehydrogenase (LDH) level and treatment response, these patients were divided into low, moderate and high risk groups.
  • They received modified B-NHL-BFM-90 protocol: cytotoxic drugs such as cyclophosphamide, vincristine, ifosfamide, etoposide, adriamycin, HD-methotrexate, vindesin, dexamethasone, cytarabinec/HD-cytarabine and intrathecal injection.
  • Of the 30 patients, 25 (83.3%) achieved complete remission (CR), 3 (10.0%) achieved partial remission (PR), 2 (6.7%) had progressive disease (PD)û 1 had tumor relapse.
  • At a median follow-up of 33 months (range, 3-98 months), the 3-year event-free survival (EFS) rate was 86.0% for all patients, with 100% for stage I/II patients and 82.1% for stage III/IV patients, 100% for low risk group, 92.0% for moderate risk group, and 70.0% for high risk group.
  • CONCLUSIONS: Modified B-NHL-BFM-90 protocol can improve the responses and survival of Burkitt's lymphoma in Chinese children and adolescents, with tolerable toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Female. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Infant. L-Lactate Dehydrogenase / blood. Leukopenia / chemically induced. Lymphatic Metastasis. Male. Neoplasm Invasiveness. Neoplasm Staging. Remission Induction. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18076797.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; EC 1.1.1.27 / L-Lactate Dehydrogenase; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


27. Darabi K, Sieber M, Chaitowitz M, Braitman LE, Tester W, Diehl V: Infradiaphragmatic versus supradiaphragmatic Hodgkin lymphoma: a retrospective review of 1,114 patients. Leuk Lymphoma; 2005 Dec;46(12):1715-20
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infradiaphragmatic versus supradiaphragmatic Hodgkin lymphoma: a retrospective review of 1,114 patients.
  • Infradiaphragmatic Hodgkin lymphoma (IDH) accounts for 4-13% of cases of stage I-II Hodgkin lymphoma (HD).
  • It has been associated with distinct pre-treatment characteristics and outcomes when compared with supradiaphragmatic HD (SDH).
  • The comparison of IDH vs SDH can only be made in early and intermediate stages (I-II), such a comparison is not possible for advanced stages (III-IV).
  • This study retrospectively compared two groups of 1013 patients with stage I-II SDH and 101 patients with IDH (10%).
  • These two sub-groups of patients were treated in 1988-1993 in 2 prospective randomized clinical trials in Germany for early and intermediate stages of Hodgkin lymphoma.
  • In early-stage unfavorable disease, IDH was associated with a higher treatment failure rate (unadjusted hazard ratio 2, 95% CI, 1.3-3.4; p = 0.003).
  • After controlling for age, sex, stage, histology, B-symptoms and involvement of 3 LNA, the adjusted hazard ratio was 1.25 (95% CI, 0.65-2.4; p = 0.51) so that IDH was no longer associated with a statistically significant treatment failure rate.
  • [MeSH-major] Hodgkin Disease / physiopathology. Hodgkin Disease / therapy
  • [MeSH-minor] Adult. Diaphragm. Female. Germany. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Randomized Controlled Trials as Topic. Retrospective Studies. Treatment Failure. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16263573.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


28. Perry SL, O'Shea SI, Byrne S, Szczech LA, Ortel TL: A multi-dose pharmacokinetic study of dalteparin in haemodialysis patients. Thromb Haemost; 2006 Dec;96(6):750-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Low-molecular-weight heparins undergo renal elimination, and therefore the proper dosing in hemodialysis (HD) patients is unclear.
  • It was the objective of this study to evaluate the pharmacokinetic (PK) parameters of dalteparin in patients receiving chronic HD for end-stage renal disease.
  • We performed a multidose PK study with prophylactic doses of dalteparin in twelve HD patients.
  • Dalteparin 5,000 IU was administered subcutaneously daily for four consecutive days, with HD performed on day 2 and day 4.
  • iii) area under the curve was 3.24 IU*hr/ml (0.64 to 6.44 IU*hr/ml);.
  • From this pilot PK study, we have determined initial PK parameters for dalteparin in HD patients.
  • Future studies to evaluate the PK parameters of dalteparin in patients receiving chronic HD may have to use weight-based dosing and will need to be performed over a longer period of time.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Area Under Curve. Body Weight. Drug Administration Schedule. Drug Monitoring. Factor Xa Inhibitors. Female. Humans. Injections, Subcutaneous. Male. Middle Aged. Pilot Projects

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17139369.001).
  • [ISSN] 0340-6245
  • [Journal-full-title] Thrombosis and haemostasis
  • [ISO-abbreviation] Thromb. Haemost.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / K12 RR17630-03; United States / NIDDK NIH HHS / DK / K23 DK02724-01A1; United States / NCRR NIH HHS / RR / M01-RR-30; United States / NCBDD CDC HHS / DD / U18DD00014; United States / NHLBI NIH HHS / HL / U54-HL077878
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Factor Xa Inhibitors; S79O08V79F / Dalteparin
  •  go-up   go-down


29. Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, Curto J, Siddiqui N, Gabra H, McLeod HL, Strathdee G, Brown R: CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res; 2005 Oct 1;65(19):8961-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have determined the methylation frequencies of 24 CpG islands of genes associated with DNA damage responses or with ovarian cancer in 106 stage III/IV epithelial ovarian tumors.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. CpG Islands. DNA (Cytosine-5-)-Methyltransferase / genetics. DNA Methylation. Female. Genotype. Humans. Middle Aged. Neoplasm Staging. Polymorphism, Genetic


30. Vrabie CD, Petrescu A, Waller M, Cojocaru M, Ciocâlteu A, Dina I: Inflammatory, degenerative and vascular lesions in long-term dialysed patients. Rom J Intern Med; 2009;47(2):149-59
MedlinePlus Health Information. consumer health - Kidney Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: The high prevalence of cardiovascular diseases in hemodialysed population suggested that the disease could begin before or during the stage of chronic renal insufficiency.
  • The detection of specific antibodies against some HCV proteins corresponding to the most conserved regions of the viral genome has been done using the immune test LiaTEK HCV III.
  • We analyzed the two groups of patients (HD/n=15; the reference group/n=30) regarding immunophenotyping, all types of lymphocytes and interleukin 2 (IL-2).
  • RESULTS: The results have classified the HD patients into three subgroups, depending on the mean of the results from flow cytometry exam, referred to normal values.
  • The assessment of the patients with or without HD to each group was made on the basis of the similar behavior of the markers investigated.
  • The most affected age group in patients with HD was 31-40 years, followed by the age group 41-50 years (26%).
  • One subgroup (A) of HD patients showed the improvement of the total number of T lymphocytes (CD3+/CD19-) after the session, while the total number of B lymphocytes was stable.
  • The third group (C) showed normal values for total T lymphocytes (CD3+/CD19-) before HD, which did not modify significantly after the session.
  • The patients had the same decreased values for B lymphocytes, which have continued to decrease after the HD (7.98%).
  • [MeSH-minor] Adult. Case-Control Studies. Female. Humans. Immunophenotyping. Interleukin-2 Receptor alpha Subunit. Killer Cells, Natural. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Dialysis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20067165.001).
  • [ISSN] 1220-4749
  • [Journal-full-title] Romanian journal of internal medicine = Revue roumaine de médecine interne
  • [ISO-abbreviation] Rom J Intern Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / IL2RA protein, human; 0 / Interleukin-2 Receptor alpha Subunit
  •  go-up   go-down


31. Roca-Tey R, Samon R, Ibrik O, Martínes-Cercós R, Viladoms J: Functional vascular access evaluation after elective intervention for stenosis. J Vasc Access; 2006 Jan-Mar;7(1):29-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To evaluate the functional effects of preventive vascular access (VA) intervention through periodic blood flow (Q A ) measurements during hemodialysis (HD) by the delta-H method.
  • METHODS: We prospectively monitored the blood flow rate (Q A ) of 100 VA (arteriovenous fistula (AVF) 81% or AV graft (AVG) 19%; mean VA duration 24.6 +/- 42.3 months) during HD in 89 end-stage renal disease patients (mean age 62.7 +/- 13.6 yrs; mean time on HD 30.9 +/- 43.9 months; 18% with diabetes) over a 3-yr period.
  • Q A was measured at least every 4 months by the delta-H method (Yarar (6)) using the Crit Line III Monitor (overall mean Q A 1247.6 +/- 519.7 ml/min).
  • Of VA with significant stenosis, 17 (17/34, 50%) VA (AVF 76.5%, AVG 23.5%; mean VA duration 12.5 +/- 22.4 months, mean percentage of VA stenosis 75.8%) in 15 patients (mean age 68.4 +/- 9.8 yrs; mean time on HD 14.2 +/- 18.2 months; 33.3% with diabetes) underwent corrective intervention by angioplasty, 35.3% (6/17), and revision surgery, 64.7% (11/17).
  • Mean Kt/V index improved from 1.44 +/- 0.24 just before intervention to 1.49 +/- 0.23 just after intervention without any change in dialyzer type or HD duration (p = 0.025).
  • 4) The HD effectiveness (Kt/V index) improved after intervention.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Constriction, Pathologic. Elective Surgical Procedures. Female. Humans. Male. Middle Aged. Renal Dialysis / adverse effects. Renal Dialysis / methods. Thrombosis / etiology. Thrombosis / prevention & control. Treatment Outcome


32. Hu MC, Davies M, Kandel DB: Epidemiology and correlates of daily smoking and nicotine dependence among young adults in the United States. Am J Public Health; 2006 Feb;96(2):299-308
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: We describe the epidemiology of smoking behaviors in a national young adult sample and identify common and unique demographic, social, and psychological correlates of daily smoking and lifetime and current nicotine dependence by race/ethnicity.
  • METHODS: Data are from the National Longitudinal Survey of Adolescent Health, wave III.
  • CONCLUSIONS: There are more common than unique correlates of each smoking stage and across racial/ethnic groups.

  • MedlinePlus Health Information. consumer health - Child Behavior Disorders.
  • MedlinePlus Health Information. consumer health - Smoking.
  • MedlinePlus Health Information. consumer health - Smoking and Youth.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Public Health. 2004 Jan;94(1):128-35 [14713710.001]
  • [Cites] Addict Behav. 2003 Oct;28(8):1447-52 [14512067.001]
  • [Cites] Annu Rev Psychol. 2004;55:463-91 [14744223.001]
  • [Cites] Am J Public Health. 2004 Feb;94(2):293-9 [14759945.001]
  • [Cites] Nicotine Tob Res. 2004 Feb;6(1):119-32 [14982696.001]
  • [Cites] Psychopharmacology (Berl). 1989;97(4):539-47 [2498951.001]
  • [Cites] Am J Public Health. 1991 Jul;81(7):854-8 [2053660.001]
  • [Cites] Br J Addict. 1991 Sep;86(9):1119-27 [1932883.001]
  • [Cites] Drug Alcohol Depend. 1993 Apr;32(2):119-25 [8508722.001]
  • [Cites] J Consult Clin Psychol. 1993 Oct;61(5):723-31 [8245270.001]
  • [Cites] J Behav Med. 1994 Jun;17(3):331-46 [7932684.001]
  • [Cites] Behav Genet. 1995 Mar;25(2):161-77 [7733857.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 1996 Dec;35(12):1602-10 [8973066.001]
  • [Cites] Drug Alcohol Depend. 1997 Jan 10;44(1):11-29 [9031816.001]
  • [Cites] J Pers Soc Psychol. 1998 Feb;74(2):387-406 [9491584.001]
  • [Cites] Prev Med. 1998 May-Jun;27(3):358-64 [9612826.001]
  • [Cites] Addiction. 1998 Apr;93(4):595-9 [9684398.001]
  • [Cites] J Adolesc Health. 1998 Sep;23(3):167-80 [9730360.001]
  • [Cites] Prev Med. 1998 Sep-Oct;27(5 Pt 3):A9-18 [9808813.001]
  • [Cites] Tob Control. 1998 Autumn;7(3):268-75 [9825422.001]
  • [Cites] Psychol Med. 1999 Mar;29(2):299-308 [10218922.001]
  • [Cites] J Behav Med. 1999 Jun;22(3):271-84 [10422618.001]
  • [Cites] Drug Alcohol Depend. 2000 May 1;59 Suppl 1:S41-60 [10773437.001]
  • [Cites] Drug Alcohol Depend. 2000 May 1;59 Suppl 1:S61-81 [10773438.001]
  • [Cites] Am J Public Health. 2000 Jul;90(7):1122-7 [10897192.001]
  • [Cites] Tob Control. 2000 Sep;9(3):313-9 [10982576.001]
  • [Cites] Nicotine Tob Res. 2000 Aug;2(3):263-74 [11082827.001]
  • [Cites] J Health Soc Behav. 2000 Dec;41(4):392-407 [11198564.001]
  • [Cites] Addict Behav. 2001 May-Jun;26(3):349-61 [11436927.001]
  • [Cites] Arch Gen Psychiatry. 2001 Sep;58(9):810-6 [11545662.001]
  • [Cites] J Sch Health. 2002 Feb;72(2):58-64 [11905130.001]
  • [Cites] Nicotine Tob Res. 2002 Feb;4(1):79-93 [11906684.001]
  • [Cites] Tob Control. 2002 Sep;11(3):228-35 [12198274.001]
  • [Cites] Addict Behav. 2004 Feb;29(2):261-72 [14732415.001]
  • (PMID = 16380569.001).
  • [ISSN] 0090-0036
  • [Journal-full-title] American journal of public health
  • [ISO-abbreviation] Am J Public Health
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / P01 HD031921; United States / NIDA NIH HHS / DA / K05 DA000081; United States / NIMH NIH HHS / MH / MH 30906; United States / NICHD NIH HHS / HD / P01 HD 31921; United States / NIDA NIH HHS / DA / R01 DA013288; United States / NIDA NIH HHS / DA / DA 00081; United States / NIDA NIH HHS / DA / DA 13288
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1470478
  •  go-up   go-down


33. Hall JE, Sullivan JP, Richardson GS: Brief wake episodes modulate sleep-inhibited luteinizing hormone secretion in the early follicular phase. J Clin Endocrinol Metab; 2005 Apr;90(4):2050-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To determine the influence of sleep, sleep stage, and time of day on the dynamics of pulsatile LH secretion in the early follicular phase (EFP) of the menstrual cycle, 11 normal women underwent simultaneous polysomnographic monitoring of sleep and measurement of LH in frequent sampling studies during a 40-h protocol that consisted of one night of normal sleep and one night of sleep deprivation followed by an afternoon nap.
  • Wakefulness was more likely to be associated with an LH pulse than were stages I/II, III/IV (slow wave), or rapid eye movement sleep (P < 0.005).
  • [MeSH-minor] Adult. Electroencephalography. Female. Humans. Time Factors. Wakefulness / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15671093.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / HD-15080; United States / NCRR NIH HHS / RR / M01 RR01066; United States / NICHD NIH HHS / HD / U54 HD29164
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-67-9 / Luteinizing Hormone
  •  go-up   go-down


34. Allen EG, Sherman S, Abramowitz A, Leslie M, Novak G, Rusin M, Scott E, Letz R: Examination of the effect of the polymorphic CGG repeat in the FMR1 gene on cognitive performance. Behav Genet; 2005 Jul;35(4):435-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To further investigate the phenotype consequence of high repeat alleles, we have analyzed Wechsler adult intelligence scales-III (WAIS-III) measures on 66 males and 217 females with a wide range of repeat sizes.
  • Because of the well established association of increasing repeat size with decreasing age at menopause, we also investigated the reproductive stage and use of hormone replacement therapy (HRT) as a covariate to model verbal intelligence quotient (VIQ).
  • [MeSH-minor] Adolescent. Adult. Brain / physiology. Cognition. Cross-Sectional Studies. Female. Fragile X Syndrome / genetics. Hormone Replacement Therapy. Humans. Intelligence Tests. Language. Magnetic Resonance Imaging. Male. Menopause. Middle Aged. Phenotype

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15971024.001).
  • [ISSN] 0001-8244
  • [Journal-full-title] Behavior genetics
  • [ISO-abbreviation] Behav. Genet.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR00039; United States / NICHD NIH HHS / HD / P01 HD35576; United States / NICHD NIH HHS / HD / R01 HD29909
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FMR1 protein, human; 139135-51-6 / Fragile X Mental Retardation Protein
  •  go-up   go-down


35. Busch M, Fleck C, Wolf G, Stein G: Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease - possible candidates for paradoxical epidemiology? Amino Acids; 2006 May;30(3):225-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease - possible candidates for paradoxical epidemiology?
  • It has been linked to atherosclerotic risk in the general population as well as in end-stage renal disease patients (ESRD), whereas symmetrical dimethylarginine (SDMA) is thought to be biological inactive.
  • Prospective data concerning the role of both dimethylarginines are rare in patients with chronic kidney disease.
  • METHODS: 200 Patients with chronic kidney disease (mean age 57.6 +/- 13.0 years, 69 female, 131 male); 82 with chronic renal failure (CRF), 81 on maintenance haemodialysis (HD) and 37 renal transplant recipients (RTR) were prospectively followed for 24 months.
  • RESULTS: Mean serum levels of SDMA were significantly increased in all groups compared to the control group (P <or= 0.0005), ADMA was increased only in HD and RTR (P <or= 0.004).
  • CONCLUSIONS: Data from a heterogeneous group of patients with chronic kidney disease provide evidence that conventional risk factors seem to play a more important role than elevated serum levels of ADMA or SDMA for cardiovascular events.
  • Whether ADMA might possibly be a candidate for the phenomenon of "paradoxical epidemiology" in chronic kidney disease needs further investigation.
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Kidney Transplantation / methods. Kidney Transplantation / mortality. Male. Middle Aged. Proportional Hazards Models. Risk Factors

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16680555.001).
  • [ISSN] 0939-4451
  • [Journal-full-title] Amino acids
  • [ISO-abbreviation] Amino Acids
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / dimethylarginine; 94ZLA3W45F / Arginine
  •  go-up   go-down


36. Wessels G, Bernard Hesseling P: Perspectives of the management of childhood lymphoma: experience at Tygerberg Hospital, Western Cape, South Africa. Transfus Apher Sci; 2005 Feb;32(1):27-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perspectives of the management of childhood lymphoma: experience at Tygerberg Hospital, Western Cape, South Africa.
  • Hodgkin's disease (HD) in children corresponds to a large degree to HD in adults.
  • Non-Hodgkin's Lymphoma (NHL) in children, however, differs from NHL in adults with respect to the classification, natural history, management and course.
  • For practical reasons clinicians generally classify and treat NHL in children as either B-cell or T-cell disease.
  • Over the past 22 years, the Paediatric Oncology Unit of the Tygerberg Hospital has treated HD with three different regimens.
  • For the last four years HD has been treated according to the regimen suggested by Schellong with good short term survival rates.
  • BFM protocols) or modified leukaemia treatments for leukaemia-lymphoma syndromes (e.g. LSA2L2).
  • The majority of patients had stage III and IV disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adult. Bleomycin / administration & dosage. Blood Transfusion. Child. Combined Modality Therapy. Dacarbazine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Humans. Mechlorethamine / administration & dosage. Prednisone / administration & dosage. Procarbazine / administration & dosage. Recurrence. South Africa. Time Factors. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15737871.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; ABVD protocol; MOPP protocol
  • [Number-of-references] 15
  •  go-up   go-down


37. Mendelssohn DC, Mujais SK, Soroka SD, Brouillette J, Takano T, Barre PE, Mittal BV, Singh A, Firanek C, Story K, Finkelstein FO: A prospective evaluation of renal replacement therapy modality eligibility. Nephrol Dial Transplant; 2009 Feb;24(2):555-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We prospectively evaluated medical and psychosocial eligibility for the three RRT modalities in patients with chronic kidney disease (CKD) stages III-V who were enrolled in an ongoing prospective cohort study conducted at seven North American nephrology practices.
  • RESULTS: Ninety-eight percent of patients were considered medically eligible for haemodialysis (HD), 87% of patients were assessed as medically eligible for peritoneal dialysis (PD) and 54% of patients were judged medically eligible for transplant.
  • The proportion of patients medically eligible for RRT did not vary by CKD stage.
  • Ninety-five percent of patients were considered psychosocially eligible for HD, 83% of patients were assessed as psychosocially eligible for PD and 71% of patients were judged psychosocially eligible for transplant.
  • The percentage of patients who were assessed as having neither medical nor psychosocial contraindications for RRT was 95% for HD, 78% for PD and 53% for transplant.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Female. Humans. Kidney Failure, Chronic / psychology. Kidney Failure, Chronic / surgery. Kidney Failure, Chronic / therapy. Kidney Transplantation / psychology. Male. Middle Aged. Peritoneal Dialysis / psychology. Prospective Studies. Psychology. Renal Dialysis / psychology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18755848.001).
  • [ISSN] 1460-2385
  • [Journal-full-title] Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • [ISO-abbreviation] Nephrol. Dial. Transplant.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


38. Trowbridge ER, Fultz NH, Patel DA, DeLancey JO, Fenner DE: Distribution of pelvic organ support measures in a population-based sample of middle-aged, community-dwelling African American and white women in southeastern Michigan. Am J Obstet Gynecol; 2008 May;198(5):548.e1-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The POP-Q stages were organized in the following manner: stage 0, 8.8%; stage I, 21.4%; stage II, 67.7%; stage III, 2.1%.

  • MedlinePlus Health Information. consumer health - Pelvic Support Problems.
  • MedlinePlus Health Information. consumer health - Urinary Incontinence.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2006 May;175(5):1769-72 [16600755.001]
  • [Cites] Arch Iran Med. 2006 Apr;9(2):124-8 [16649354.001]
  • [Cites] Am J Obstet Gynecol. 2000 Aug;183(2):277-85 [10942459.001]
  • [Cites] Am J Obstet Gynecol. 2002 Apr;186(4):712-6 [11967496.001]
  • [Cites] Am J Obstet Gynecol. 2005 Mar;192(3):795-806 [15746674.001]
  • [Cites] Obstet Gynecol. 2004 Sep;104(3):489-97 [15339758.001]
  • [Cites] Am J Obstet Gynecol. 1996 Jul;175(1):10-7 [8694033.001]
  • [Cites] Am J Obstet Gynecol. 1996 Dec;175(6):1467-70; discussion 1470-1 [8987926.001]
  • [Cites] Am J Obstet Gynecol. 1999 Feb;180(2 Pt 1):299-305 [9988790.001]
  • [Cites] Am J Obstet Gynecol. 2002 Jun;186(6):1160-6 [12066091.001]
  • (PMID = 18455530.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / HD041123-05; United States / NICHD NIH HHS / HD / R01 HD041123; United States / NICHD NIH HHS / HD / R01 HD 041123; United States / NICHD NIH HHS / HD / R01 HD041123-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS118140; NLM/ PMC2753829
  •  go-up   go-down


39. Buhimschi IA, Zambrano E, Pettker CM, Bahtiyar MO, Paidas M, Rosenberg VA, Thung S, Salafia CM, Buhimschi CS: Using proteomic analysis of the human amniotic fluid to identify histologic chorioamnionitis. Obstet Gynecol; 2008 Feb;111(2 Pt 1):403-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The prevalence of histologic chorioamnionitis was 64% (stage I 12%, stage II 16%, and stage III 37%).
  • Of the four biomarkers of the Mass Restricted score, calgranulin C had the strongest relationship with presence of stage III chorioamnionitis, independent of race, amniocentesis-to-delivery interval, and gestational age.

  • MedlinePlus Health Information. consumer health - Infections and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18238979.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / R01 HD047321-01; United States / NICHD NIH HHS / HD / R01 HD047321; United States / NICHD NIH HHS / HD / R01 HD047321-05; United States / NICHD NIH HHS / HD / R01 HD 047321-01; United States / NICHD NIH HHS / HD / R01 HD047321-03; United States / NICHD NIH HHS / HD / R01 HD047321-02; United States / NICHD NIH HHS / HD / R01 HD047321-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Proteome
  •  go-up   go-down


40. Roth EB, Jeffe DB, Margenthaler JA, Aft RL: Method of breast cancer presentation and depressed mood 1 year after diagnosis in women with locally advanced disease. Ann Surg Oncol; 2009 Jun;16(6):1637-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Method of breast cancer presentation and depressed mood 1 year after diagnosis in women with locally advanced disease.
  • BACKGROUND: Differences in psychological outcomes of breast cancer patients with locally advanced disease who presented with abnormal screening mammograms or palpable mass have not been reported.
  • METHODS: We interviewed 120 women with clinical stage II/III breast cancer enrolled onto a prospective phase 2 clinical trial at diagnosis and 1 year after diagnosis, inquiring about demographics, depressive symptoms, social support, and perceived risk of disease recurrence.
  • RESULTS: A significant interaction was observed between presentation method and change in depressed mood among 86 women without disease progression who completed both interviews.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Depression.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Behav Med. 1999 Summer;21(3):201-9 [10626025.001]
  • [Cites] Psychooncology. 1999 May-Jun;8(3):264-7 [10390739.001]
  • [Cites] Soc Sci Med. 1991;32(6):705-14 [2035047.001]
  • [Cites] J Psychosom Res. 1989;33(1):1-5 [2926697.001]
  • (PMID = 19360452.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA091842; United States / NCI NIH HHS / CA / P30 CA91842; United States / NICHD NIH HHS / HD / T32 HD052266
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS562260; NLM/ PMC3982328
  •  go-up   go-down


41. Kovács AF, Mose S, Böttcher HD, Bitter K: Multimodality treatment including postoperative radiation and concurrent chemotherapy with weekly docetaxel is feasible and effective in patients with oral and oropharyngeal cancer. Strahlenther Onkol; 2005 Jan;181(1):26-34
Hazardous Substances Data Bank. SODIUM THIOSULFATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: 94 patients (Table 1) with primary resectable squamous cell carcinoma of the oral cavity and oropharynx (UICC stage I 14%, II 15%, III 18%, IV 53%; Table 2) were treated with a multimodality therapy program consisting of neoadjuvant intra-arterial high-dose chemotherapy (cisplatin 150 mg/m(2) with parallel systemic sodium thiosulfate 9 g/m(2) for neutralization), followed by surgery of the primary and neck, and postoperative concurrent radiation and chemotherapy with weekly docetaxel (20-30 mg/m(2); Table 3).
  • RESULTS: At a median follow-up of 4 years, the 5-year survival rate for all 94 patients was 80%, and disease-free survival was 73% (Figures 1 and 2).
  • Among patients with advanced disease (stage III and IV), survival was 83 and 59%, respectively (Figure 4).
  • CONCLUSIONS: Concurrent radiation and chemotherapy with weekly docetaxel is a feasible postoperative treatment in a multimodality approach to oral and oropharyngeal cancer, resulting in high overall and disease-free survival.
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Cisplatin / administration & dosage. Cisplatin / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Feasibility Studies. Female. Follow-Up Studies. Head / pathology. Humans. Infusions, Intravenous. Injections, Intra-Arterial. Male. Middle Aged. Neck / pathology. Neck Dissection. Neoadjuvant Therapy. Neoplasm Staging. Postoperative Care. Radiotherapy Dosage. Survival Analysis. Thiosulfates / administration & dosage. Thiosulfates / therapeutic use. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15660190.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 0 / Thiosulfates; 15H5577CQD / docetaxel; HX1032V43M / sodium thiosulfate; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


42. Hundley AF, Yuan L, Visco AG: Skeletal muscle heavy-chain polypeptide 3 and myosin binding protein H in the pubococcygeus muscle in patients with and without pelvic organ prolapse. Am J Obstet Gynecol; 2006 May;194(5):1404-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Specimens were obtained from 17 patients with stage III or IV pelvic organ prolapse and 23 controls with minimal to no prolapse.
  • [MeSH-minor] Adult. Aged. Body Mass Index. Case-Control Studies. Computer Systems. Female. Humans. Middle Aged. Pelvic Floor. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Pelvic Support Problems.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16579921.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / R01-HD-38680
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytoskeletal Proteins; 0 / MYBPH protein, human; 0 / MYH3 polypeptide, human
  •  go-up   go-down


43. Soleymanian T, Raman S, Shannaq FN, Richardson R, Jassal SV, Bargman J, Oreopoulos DG: Survival and morbidity of HIV patients on hemodialysis and peritoneal dialysis: one center's experience and review of the literature. Int Urol Nephrol; 2006;38(2):331-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Total follow-up of HIV-infected PD and HD patients was 248.3 and 207 patient months, respectively.
  • There was no significant difference in hospitalization rate between HIV-infected PD and HD patients (1.01 and 1.39 admission/year, respectively, P = NS).
  • Survival of HIV-infected patients on PD at one, two and three years was 100, 83, and 50%, and for HD patients was 75, 33, and 33%, respectively.
  • HIV-infected patients on HD had more prevalent advanced HIV disease.
  • Two out of seven PD patients were on PD for more than five years and one of the HD patients was on that form of dialysis for more than nine years.
  • Median survival of patients with advanced (Stage IV) AIDS (both HD and PD) was 15.1 months (range 1.6-17.3) while this value for non-advanced (Stage II, III) patients was 61.2 months (range 6.8-116.6).
  • Survival is worse in patients with advanced HIV disease.
  • [MeSH-minor] Adult. Comorbidity. Female. Follow-Up Studies. Hospitalization. Humans. Male. Middle Aged. Peritoneal Dialysis / adverse effects. Peritoneal Dialysis / mortality. Retrospective Studies. Survival Analysis


44. Guadagnolo BA, Punglia RS, Kuntz KM, Mauch PM, Ng AK: Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease. J Clin Oncol; 2006 Sep 1;24(25):4116-22
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease.
  • PURPOSE: To estimate the clinical benefits and cost effectiveness of computed tomography (CT) in the follow-up of patients with complete response (CR) after treatment for Hodgkin's disease (HD).
  • PATIENTS AND METHODS: We developed a decision-analytic model to evaluate follow-up strategies for two hypothetical cohorts of 25-year-old patients with stage I-II or stage III-IV HD, treated with doxorubicin, bleomycin, vinblastine, and dacarbazine-based chemotherapy with or without radiation therapy, respectively.
  • With adjustments for quality of life, we found a decrement in quality-adjusted life expectancy for early-stage patients followed with CT compared with non-CT modalities.
  • For advanced-stage patients, annual CT for 5 years is associated with a very small quality-adjusted survival gain over non-CT follow-up with an incremental cost-effectiveness ratio of 9,042,300 dollars/QALY.
  • CONCLUSION: Our analysis suggests that routine CT should not be used in the surveillance of asymptomatic patients in CR after treatment for HD.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Decision Support Techniques. Hodgkin Disease / economics. Hodgkin Disease / radiography. Population Surveillance / methods. Tomography, X-Ray Computed / economics
  • [MeSH-minor] Adult. Bleomycin / administration & dosage. Cost-Benefit Analysis. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Humans. Life Expectancy. Markov Chains. Neoplasm Staging. Predictive Value of Tests. Quality-Adjusted Life Years. Sensitivity and Specificity. Survival Analysis. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16943528.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5 R25 CA57711-11
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin
  •  go-up   go-down


45. Kepka L, Suit HD, Goldberg SI, Rosenberg AE, Gebhardt MC, Hornicek FJ, Delaney TF: Results of radiation therapy performed after unplanned surgery (without re-excision) for soft tissue sarcomas. J Surg Oncol; 2005 Oct 1;92(1):39-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor characteristics: location, lower extremity (63%), upper extremity (27%), other (10%); median tumor size, 5 cm; grade-G1 (19%), G2 (49%), G3 (32%); AJCC stage (2002)-I (19%), II (54%), III (27%).
  • Depth in the relation to the fascia, tumor size, and AJCC stage significantly influenced local recurrence- and distant metastasis-free survival.
  • [MeSH-minor] Adolescent. Adult. Aged. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Radiotherapy / adverse effects. Radiotherapy Dosage. Retrospective Studies. Survival Analysis. Treatment Failure

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16180232.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Nygaard I, Handa V, Brubaker L, Borello-France D, Wei J, Wells E, Weber AM, Pelvic Floor Disorders Network: Physical activity in women planning sacrocolpopexy. Int Urogynecol J Pelvic Floor Dysfunct; 2007 Jan;18(1):33-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Activity frequencies did not generally differ by prolapse stage.
  • Prolapse stage was not associated with interference with household/yard work (p=0.28) or work outside home (p=0.89).
  • Although prolapse stage is associated with interference with recreation (p=0.02), this association is not consistently positive : stage II, 42%; stage III, 22%; and stage IV, 32%.
  • [MeSH-minor] Adult. Aged. Female. Gynecologic Surgical Procedures. Housekeeping. Humans. Middle Aged. Prolapse. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Exercise and Physical Fitness.
  • MedlinePlus Health Information. consumer health - Exercise for Seniors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Obstet Gynecol. 1999 Feb;180(2 Pt 1):299-305 [9988790.001]
  • [Cites] J Clin Epidemiol. 1998 Nov;51(11):903-12 [9817107.001]
  • [Cites] Am J Obstet Gynecol. 1996 Jul;175(1):10-7 [8694033.001]
  • [Cites] Can J Appl Sport Sci. 1985 Sep;10(3):141-6 [4053261.001]
  • [Cites] Am J Obstet Gynecol. 2003 Jan;188(1):108-15 [12548203.001]
  • [Cites] J Am Geriatr Soc. 1968 May;16(5):622-6 [5646906.001]
  • [Cites] Control Clin Trials. 2003 Oct;24(5):629-42 [14500059.001]
  • [Cites] Am J Obstet Gynecol. 2002 Jul;187(1):88-92 [12114893.001]
  • [Cites] Am J Obstet Gynecol. 2001 Dec;185(6):1388-95 [11744914.001]
  • [Cites] Am J Obstet Gynecol. 2002 Jun;186(6):1160-6 [12066091.001]
  • [Cites] Obstet Gynecol. 1990 May;75(5):848-51 [2325968.001]
  • [Cites] N Engl J Med. 2006 Apr 13;354(15):1557-66 [16611949.001]
  • (PMID = 16688397.001).
  • [Journal-full-title] International urogynecology journal and pelvic floor dysfunction
  • [ISO-abbreviation] Int Urogynecol J Pelvic Floor Dysfunct
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / U01 HD41249; United States / NICHD NIH HHS / HD / U10 HD41248; United States / NICHD NIH HHS / HD / U10 HD41250; United States / NICHD NIH HHS / HD / U10 HD41261; United States / NICHD NIH HHS / HD / U10 HD41263; United States / NICHD NIH HHS / HD / U10 HD41267; United States / NICHD NIH HHS / HD / U10 HD41268; United States / NICHD NIH HHS / HD / U10 HD41269
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  •  go-up   go-down


47. Salem HA, Eissa LA, Rabbie AM, El-Helw LM, El-Gayar AM: Evaluation of some biochemical markers as prognostic factors in malignant lymphomas. Pak J Pharm Sci; 2006 Jul;19(3):219-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Also, the work aimed to investigate the relationship between these levels with B symptoms and disease stage.
  • For this purpose, 43 newly diagnosed patients with malignant lymphoma (12 with Hodgkin's disease (HD) and 31 with Non-Hodgkin's lymphoma (NHL) were selected from Mansoura University Hospital.
  • Among NHL patients, 7 were in stage I/II, 13 in stage III and 14 in stage IV.
  • RESULTS: 1-Pre-treatment levels of GAGs, sp55TNF-R and sL-selectin increased significantly in both HD and NHL before treatment as compared to control.
  • Pre-treatment sp55TNF-R levels in both diseases and sL-selectin (only in HD patients) may have a significant value in predicting response to therapy, while GAGs level in both diseases and sL-selectin in NHL patients had a limited value in such prediction.
  • 2- In contrast to sp55TNF-R and sL-selectin, post-treatment GAG levels are thought to be a good sign of remission in both HD and NHL.
  • 3- Serum GAG levels increased significantly before treatment in stages III/IV NHL as compared to stage I/II, so serum GAGs at diagnosis could reflect tumor bulk and the disease activity.
  • CONCLUSION: Pre-treatment sp55TNF-R levels in both HD & NHL and sL-selectin (only in HD patients) could be used as prognostic factor with respect to predicting treatment outcome.
  • Serum GAGs at diagnosis could reflect tumor bulk and the disease activity.
  • [MeSH-major] Biomarkers, Tumor. Lymphoma / metabolism
  • [MeSH-minor] Adolescent. Adult. Blood Cell Count. Blood Sedimentation. Female. Glycosaminoglycans / metabolism. Humans. Kidney Function Tests. L-Lactate Dehydrogenase / metabolism. L-Selectin / metabolism. Liver Function Tests. Male. Middle Aged. Neoplasm Staging. Prognosis. Receptors, Tumor Necrosis Factor, Type I / metabolism

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16935830.001).
  • [ISSN] 1011-601X
  • [Journal-full-title] Pakistan journal of pharmaceutical sciences
  • [ISO-abbreviation] Pak J Pharm Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glycosaminoglycans; 0 / Receptors, Tumor Necrosis Factor, Type I; 126880-86-2 / L-Selectin; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


48. Akhtar S, Tbakhi A, Humaidan H, El Weshi A, Rahal M, Maghfoor I: ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients. Bone Marrow Transplant; 2006 Feb;37(3):277-82
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients.
  • From 1996 to November 2004, 131 consecutive patients with relapsed or refractory diffuse large cell lymphoma (DLCL) and Hodgkin's lymphoma (HD) received ESHAP as mobilization chemotherapy before autologous peripheral blood stem cell transplant (ASCT).
  • DLCL 49: HD 78.
  • Initial stage I:II:III:IV:unknown was 15:34:33:42:3.
  • Median total CD34+ cells/kg collected were 6.9 x 10(6) (DLCL 5.17 x 10(6) and HD 7.6 x 10(6)), patients weighing < or = 70 kg (93 patients) 6.54 x 10(6) and >70 kg (34 patients) 7.44 x 10(6) (P = 0.59), one apheresis (93 patients) 8.6 x 10(6)/kg and >1 apheresis (34 patients) 4.5 x 10(6) (P = 0.001).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Granulocyte Colony-Stimulating Factor / administration & dosage. Hematopoietic Stem Cell Mobilization. Hodgkin Disease / therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adult. Blood Component Removal / methods. Cisplatin / administration & dosage. Cytarabine / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Methylprednisolone / administration & dosage. Recurrence. Retrospective Studies. Transplantation, Autologous

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16400345.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; X4W7ZR7023 / Methylprednisolone; ESAP protocol
  •  go-up   go-down


49. Dilek I, Ayakta H, Demir C, Meral C, Ozturk M: CA 125 levels in patients with non-Hodgkin lymphoma and other hematologic malignancies. Clin Lab Haematol; 2005 Feb;27(1):51-5
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CA 125 levels in patients with non-Hodgkin lymphoma and other hematologic malignancies.
  • The study group included 69 non-Hodgkin lymphomas (NHL), 25 Hodgkin disease (HD), 20 acute myelocytic leukemia (AML), 14 chronic lymphocytic leukemia (CLL), 12 chronic myelocytic leukemia (CML), and nine multiple myeloma (MM) patients.
  • CA 125 levels were significantly higher in NHL patients with abdominal involvement (113.6 +/- 23.4 U/ml), with B-symptoms (72.3 +/- 13.2 U/ml), higher stage of the disease (stages III and IV -75.3 +/- 14.9 U/ml), bulky disease (99.9 +/- 30.4 U/ml) and in those with serosal involvement (103.1 +/- 18.5 U/ml) (P < 0.05 for all).
  • CA 125 levels were also elevated in seven patients with HD and in a patient with CLL with pleural effusion.
  • In conclusion, for patients with NHL, high levels of CA 125 were associated with B-symptoms, advanced stage, bulky disease, abdominal, and serosal involvement.
  • Therefore, CA 125 might be used as a marker to predict prognosis and to detect advanced disease in NHL.
  • [MeSH-major] CA-125 Antigen / blood. Hematologic Neoplasms / blood. Hematologic Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / blood. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Leukemia / blood. Leukemia / classification. Leukemia / diagnosis. Male. Middle Aged

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15686508.001).
  • [ISSN] 0141-9854
  • [Journal-full-title] Clinical and laboratory haematology
  • [ISO-abbreviation] Clin Lab Haematol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


50. Asmis LM, Segal JB, Plantinga LC, Fink NE, Kerman JS, Kickler TS, Coresh J, Gardner LB: Heparin-induced antibodies and cardiovascular risk in patients on dialysis. Thromb Haemost; 2008 Sep;100(3):498-504
Zurich Open Access Repository and Archive. Full text from .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aims of this study were (i) to determine the prevalence of HIA in patients treated by dialysis, (ii) to determine the prevalence of thrombocytopenia and heparin-induced thrombocytopenia (HIT), and (iii) to test whether HIA are associated with adverse outcomes.
  • Sera from 740 patients treated by hemodialysis (HD, n=596) and peritoneal dialysis (PD, n=144) were tested for HIA (IgG, IgA or IgM) by masked investigators at approximately six months after enrolment in the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) study.
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunoglobulin A / analysis. Immunoglobulin G / analysis. Immunoglobulin M / analysis. Male. Middle Aged. Peritoneal Dialysis. Platelet Count. Renal Dialysis. Risk

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HEPARIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18766268.001).
  • [ISSN] 0340-6245
  • [Journal-full-title] Thrombosis and haemostasis
  • [ISO-abbreviation] Thromb. Haemost.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01-RR000052; United States / NIDDK NIH HHS / DK / R01-DK-59616; United States / NHLBI NIH HHS / HL / R01-HL-62985
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies; 0 / Immunoglobulin A; 0 / Immunoglobulin G; 0 / Immunoglobulin M; 9005-49-6 / Heparin
  •  go-up   go-down


51. Matos JM, Grützmann R, Agaram NP, Saeger HD, Kumar HR, Lillemoe KD, Schmidt CM: Solid pseudopapillary neoplasms of the pancreas: a multi-institutional study of 21 patients. J Surg Res; 2009 Nov;157(1):e137-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AJCC stages were stage I (18), stage II (1), stage III (2), and stage IV (0).
  • [MeSH-minor] Adolescent. Adult. Female. Follow-Up Studies. Humans. Male. Middle Aged. Postoperative Complications. Retrospective Studies. Tomography, X-Ray Computed. Young Adult

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Surg Res. 2010 Nov;164(1):74
  • (PMID = 19818965.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


52. Jones CJ, Inuwa IM, Nardo LG, Litta P, Fazleabas AT: Eutopic endometrium from women with endometriosis shows altered ultrastructure and glycosylation compared to that from healthy controls--a pilot observational study. Reprod Sci; 2009 Jun;16(6):559-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ultrastructural analysis of glandular endometrial tissue from women with stages I to III endometriosis showed heterogeneous responses to the disease, biopsies often showing a mixture of features, combining delays in the maturation sequence with characteristics of later phenotypes particularly in the mid-late secretory phase of the menstrual cycle.
  • Biopsies from women with stage IV endometriosis showed immature gland morphology later in the cycle and also failed to express Dolichos biflorus agglutinin-binding glycans, suggesting an association between histological and biochemical function in advanced disease states.

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19282503.001).
  • [ISSN] 1933-7205
  • [Journal-full-title] Reproductive sciences (Thousand Oaks, Calif.)
  • [ISO-abbreviation] Reprod Sci
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / U54 HD040093; United States / NICHD NIH HHS / HD / U54HD 40093
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


53. Gocheva L, Koleva I: Long-term outcome of treatment for Hodgkin's disease: the University Hospital Sofia experience. Klin Onkol; 2010;23(1):34-42
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of treatment for Hodgkin's disease: the University Hospital Sofia experience.
  • BACKGROUND: To establish the efficacy of the combined modality treatment (CMT) including curative extended field radiotherapy (EFRT) and chemotherapy (CHT) by examining the long-term outcome in Hodgkin's disease (HD) patients at the Sofia University Hospital "Queen Giovanna-ISUL", with particular focus on second primary malignancy (SPM), and to establish independent factors correlated with treatment outcome.
  • METHODS AND MATERIALS: Between 1982 and 2007, 170 patients with HD with median age of 12 years (range 3-40), (68 females, 102 males), were included in this retrospective study.
  • The clinical stage (CS) distribution was CS I in 1 patient (0.6%), CS II in 86 (50.5%), CS III in 77 (45.3%) and CS IV in 6 (3.5%) patients.
  • The following factors were analyzed for their prognostic influence: age, gender, stage, histologic subtype at first diagnosis, sites of involvement, number of involved lymph node areas, B symptoms, hepatosplenomegaly, anemia, elevated serum LDH, daily dose, total dose, boost and technique used in EFRT.
  • In univariate analysis, independent risk factors were gender (p < 0.001), stage (IIB: IIIA) (p = 0.03), mediastinal involvement (p = 0.03), daily dose (p = 0.01) and total dose (p = 0.02).
  • We investigated a prognostic model, identifying groups of HD patients with particularly responsive disease, combining prognostic factors as age < or = 15 years (p = 0.001), male gender (p = 0.011), and total dose 26-30 Gy (p = 0.012).
  • CONCLUSION: The performed first Bulgarian study on CMT including EFRT and CHT exhibited a certain therapeutic potential in the treatment of HD patients, expressed in the achievement of high long term outcome and low SPM frequency.
  • [MeSH-major] Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Prognosis. Risk Factors. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20192072.001).
  • [ISSN] 0862-495X
  • [Journal-full-title] Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti
  • [ISO-abbreviation] Klin Onkol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


54. El Kelany MA, Maklad SS, El Fouhil DF, El Etreby EA, Saleh LH, El Sheikh NA: Immunomodulatory effects of secondary hyperparathyroidism on circulating CD4+ and CD8+ T-lymphocytes in chronic renal failure patients. Egypt J Immunol; 2009;16(2):71-82

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The immunomodulatory effects of parathyroid hormone (PTH) in patients with end stage renal disease (ESRD) is controversial.
  • This study was carried out to investigate the effect of PTH levels on the circulating CD4+, CD8+ T cell counts (%) in patients with chronic renal failure (CRF) on regular hemodialysis ((HD).
  • The study included 22 patients with serum levels of PTH < 300 pg/ml (group 1), 18 patients with PTH > 300 pg/ml (group II) and 10 age and sex matched normal controls (group III).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22059355.001).
  • [ISSN] 1110-4902
  • [Journal-full-title] The Egyptian journal of immunology
  • [ISO-abbreviation] Egypt J Immunol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Antigens, CD4; 0 / Antigens, CD8; 0 / Parathyroid Hormone; 9007-41-4 / C-Reactive Protein
  •  go-up   go-down


55. Makhsous M, Lin F, Knaus E, Zeigler M, Rowles DM, Gittler M, Bankard J, Chen D: Promote pressure ulcer healing in individuals with spinal cord injury using an individualized cyclic pressure-relief protocol. Adv Skin Wound Care; 2009 Nov;22(11):514-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PARTICIPANTS: Forty-four subjects, aged 18-79 years, with a Stage II or Stage III PrU, were randomly assigned to the control (n = 22) or treatment (n = 22) groups.

  • MedlinePlus Health Information. consumer health - Pressure Sores.
  • MedlinePlus Health Information. consumer health - Spinal Cord Injuries.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 1987 Nov;107(5):641-8 [3310792.001]
  • [Cites] Geriatr Nurs. 1989 Jul-Aug;10(4):190-2 [2777121.001]
  • [Cites] J Rehabil Res Dev. 1990 Spring;27(2):141-50 [2366198.001]
  • [Cites] JAMA. 1990 Dec 12;264(22):2905-9 [2232085.001]
  • [Cites] West J Med. 1991 May;154(5):539-44 [1830985.001]
  • [Cites] J Rehabil Res Dev. 1992 Fall;29(4):21-31 [1432724.001]
  • [Cites] JAMA. 1993 Jan 27;269(4):494-7 [8338511.001]
  • [Cites] Arch Phys Med Rehabil. 1993 Sep;74(9):947-53 [8379841.001]
  • [Cites] Arch Phys Med Rehabil. 1994 May;75(5):535-9 [8185445.001]
  • [Cites] Paraplegia. 1995 Mar;33(3):141-7 [7784116.001]
  • [Cites] Ostomy Wound Manage. 1997 Jan-Feb;43(1):28-32, 34-5, 38; quiz 39-40 [9087064.001]
  • [Cites] Ann Intern Med. 1981 May;94(5):661-6 [7235399.001]
  • [Cites] Ostomy Wound Manage. 2004 Oct;50(10):40-2, 44-52; discussion 53 [15509881.001]
  • [Cites] Am J Health Syst Pharm. 2004 Sep 15;61(18):1895-905; quiz 1906-7 [15487879.001]
  • [Cites] Am J Surg. 2004 Jul;188(1A Suppl):9-17 [15223496.001]
  • [Cites] Cochrane Database Syst Rev. 2000;(2):CD001735 [10796662.001]
  • [Cites] Spinal Cord. 2003 Dec;41(12):692-5 [14639449.001]
  • [Cites] Nurs Manag (Harrow). 2003 Oct;Suppl:6-10, 12-4; quiz 14-5 [14694861.001]
  • [Cites] Arch Phys Med Rehabil. 2001 Apr;82(4):529-33 [11295017.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2001 Dec;56(12):M795-9 [11723157.001]
  • [Cites] Wound Repair Regen. 2001 Sep-Oct;9(5):347-52 [11896977.001]
  • [Cites] Scand J Plast Reconstr Surg Hand Surg. 2002;36(5):279-83 [12477086.001]
  • [Cites] Surg Technol Int. 2003;11:23-31 [12931279.001]
  • [Cites] Ann Intern Med. 2003 Oct 21;139(8):635-41 [14568851.001]
  • [Cites] J Spinal Cord Med. 2007;30(5):497-507 [18092567.001]
  • [Cites] Arch Phys Med Rehabil. 2007 Jul;88(7):862-70 [17601466.001]
  • [Cites] Arch Phys Med Rehabil. 2006 Oct;87(10):1396-402 [17023252.001]
  • [Cites] Adv Skin Wound Care. 2006 Sep;19(7):398-405; quiz 405-7 [16943709.001]
  • [Cites] JAMA. 2006 Aug 23;296(8):974-84 [16926357.001]
  • [Cites] Plast Reconstr Surg. 1998 Sep;102(3):765-72 [9727442.001]
  • [Cites] Adv Wound Care. 1998 Sep;11(5):237-46 [10326341.001]
  • [Cites] Arch Phys Med Rehabil. 1961 Jan;42:19-29 [13753341.001]
  • (PMID = 20026933.001).
  • [ISSN] 1538-8654
  • [Journal-full-title] Advances in skin & wound care
  • [ISO-abbreviation] Adv Skin Wound Care
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / HD046844-01A1S1; United States / NICHD NIH HHS / HD / R21 HD046844; United States / NICHD NIH HHS / HD / HD047959-01; United States / NICHD NIH HHS / HD / R21 HD046844-01A1; United States / NICHD NIH HHS / HD / HD046844-02; United States / NICHD NIH HHS / HD / R21 HD046844-01A1S1; United States / NICHD NIH HHS / HD / R21 HD046844-02; United States / NICHD NIH HHS / HD / R41 HD047959; United States / NICHD NIH HHS / HD / R41 HD047959-01; United States / NICHD NIH HHS / HD / HD046844-01A1
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS167781; NLM/ PMC2860306
  •  go-up   go-down


56. Kent SC, Gnatuk CL, Kunselman AR, Demers LM, Lee PA, Legro RS: Hyperandrogenism and hyperinsulinism in children of women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab; 2008 May;93(5):1662-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN: We performed a case control study of PCOS children (n = 32) compared with children from control women (n = 38) for reproductive and metabolic abnormalities, stratifying results by three Tanner stage groupings.
  • Urine testosterone levels were significantly elevated in Tanner II-III PCOS boys compared with controls (P = 0.007).
  • We validated the correlation between salivary and serum levels of insulin (insulin areas under the curve) in an adult population [n =30, Pearson correlation coefficient (r) = 0.67; P < 0.0001], which also replicated in the children (2-h insulin r = 0.57; P = 0.0004).

  • Genetic Alliance. consumer health - Hyperandrogenism.
  • MedlinePlus Health Information. consumer health - Polycystic Ovary Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Reprod Update. 2006 Nov-Dec;12(6):673-83 [16891296.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Oct;91(10):4112-7 [16868051.001]
  • [Cites] N Engl J Med. 2007 Feb 8;356(6):551-66 [17287476.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Mar;92(3):787-96 [17179197.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jul;92(7):2739-43 [17488788.001]
  • [Cites] Metabolism. 2008 Jan;57(1):84-9 [18078863.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Jan;80(1):172-8 [7829608.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Apr;90(4):2136-41 [15644405.001]
  • [Cites] Hum Reprod. 2005 Aug;20(8):2122-6 [15802312.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Aug;90(8):4797-802 [15899949.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Feb;91(2):492-7 [16249280.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 2;103(18):7030-5 [16632599.001]
  • [Cites] J Clin Endocrinol Metab. 2006 May;91(5):1714-22 [16492701.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Feb;92(2):430-6 [17118995.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Mar;85(3):1021-5 [10720033.001]
  • [Cites] Science. 2000 Sep 22;289(5487):2122-5 [11000114.001]
  • [Cites] Am J Med. 2001 Dec 1;111(8):607-13 [11755503.001]
  • [Cites] J Clin Endocrinol Metab. 2002 May;87(5):2128-33 [11994352.001]
  • [Cites] J Clin Endocrinol Metab. 2002 May;87(5):2134-8 [11994353.001]
  • [Cites] Fertil Steril. 2002 Sep;78(3):569-76 [12215335.001]
  • [Cites] Fertil Steril. 2004 Jan;81(1):19-25 [14711538.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jun;89(6):2622-31 [15181033.001]
  • [Cites] Circulation. 2004 Oct 19;110(16):2494-7 [15477412.001]
  • [Cites] Clin Chem. 1972 Jun;18(6):499-502 [4337382.001]
  • [Cites] Contraception. 1974 Dec;10(6):599-605 [4448070.001]
  • [Cites] J Clin Endocrinol Metab. 1975 May;40(5):783-89 [1173241.001]
  • [Cites] J Clin Invest. 1976 May;57(5):1320-9 [770505.001]
  • [Cites] Clin Chem. 1981 Nov;27(11):1892-5 [6794948.001]
  • [Cites] Diabetologia. 1985 Jul;28(7):412-9 [3899825.001]
  • [Cites] Lancet. 1985 Dec 21-28;2(8469-70):1375-9 [2867389.001]
  • [Cites] Diabetologia. 1986 Oct;29(10):695-8 [3542670.001]
  • [Cites] Public Health Rep. 1988 Mar-Apr;103(2):143-7 [3128829.001]
  • [Cites] Diabetes Care. 1988 Jun;11(6):489-94 [3042316.001]
  • [Cites] Am J Clin Nutr. 1991 Dec;54(6):1005-10 [1957814.001]
  • [Cites] Ultrasound Med Biol. 1991;17(6):589-93 [1962361.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Apr;81(4):1353-6 [8636332.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Mar;81(3):942-7 [8772555.001]
  • [Cites] Pediatrics. 1996 Oct;98(4 Pt 1):649-58 [8885941.001]
  • [Cites] Lancet. 1997 Oct 18;350(9085):1131-5 [9343501.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14956-60 [9843997.001]
  • [Cites] Ann Epidemiol. 2006 Jun;16(6):429-31 [16280248.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Aug;91(8):3105-9 [16720659.001]
  • [CommentIn] J Clin Endocrinol Metab. 2008 May;93(5):1576-8 [18463351.001]
  • (PMID = 18270257.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / C06 RR 016499; United States / NCRR NIH HHS / RR / M01 RR010732; United States / NICHD NIH HHS / HD / K24 HD001476; United States / NICHD NIH HHS / HD / U54 HD 034449; United States / NCRR NIH HHS / RR / C06 RR016499; United States / NICHD NIH HHS / HD / U54 HD034449; United States / NICHD NIH HHS / HD / K24 HD 01476; United States / NCRR NIH HHS / RR / M01 RR 10732
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gonadotropins; 0 / Insulin; 0 / Lipids
  • [Other-IDs] NLM/ PMC2386683
  •  go-up   go-down


57. Ripperger T, Tröger HD, Schmidtke J: The genetic message of a sudden, unexpected death due to thoracic aortic dissection. Forensic Sci Int; 2009 May 30;187(1-3):1-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, for at-risk relatives of the deceased, it could be of great benefit to be alerted to the potential heritable aetiology, because early diagnosis of the latent stage of the disease would allow preventive management.
  • We report here on three cases to underline the practical relevance of (i) documentation of relevant information for differential diagnosis of TAAD-associated disorders, (ii) storage of unfixed tissue samples for subsequent molecular genetic testing, and most importantly (iii) the information of relatives at risk.
  • [MeSH-minor] Adult. Diagnosis, Differential. Fatal Outcome. Female. Humans. Male. Marfan Syndrome / diagnosis. Marfan Syndrome / genetics. Microfilament Proteins / analysis. Molecular Biology. Mutation. Protein-Serine-Threonine Kinases / analysis. Receptors, Transforming Growth Factor beta / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19285815.001).
  • [ISSN] 1872-6283
  • [Journal-full-title] Forensic science international
  • [ISO-abbreviation] Forensic Sci. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Microfilament Proteins; 0 / Receptors, Transforming Growth Factor beta; 0 / fibrillin; EC 2.7.1.11 / TGF-beta type I receptor; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor
  •  go-up   go-down


58. Schleinitz MD, DePalo D, Blume J, Stein M: Can differences in breast cancer utilities explain disparities in breast cancer care? J Gen Intern Med; 2006 Dec;21(12):1253-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We incorporated each subject's utilities into a Markov model to determine whether her quality-adjusted life expectancy would be maximized with chemotherapy for a hypothetical, current diagnosis of stage II breast cancer.
  • RESULTS: Median utilities for the 8 health states were: stage I disease, 0.91 (interquartile range 0.50 to 1.00); stage II, 0.75 (0.26 to 0.99); stage III, 0.51 (0.25 to 0.94); stage IV (estrogen receptor positive), 0.36 (0 to 0.75); stage IV (estrogen receptor negative), 0.40 (0 to 0.79); chemotherapy 0.50 (0 to 0.92); hormonal therapy 0.58 (0 to 1); and radiation therapy 0.83 (0.10 to 1).
  • Utilities for early stage disease and treatment modalities, but not metastatic disease, varied with socio-demographic characteristics.
  • One hundred and twenty-two of 156 subjects had utilities that maximized quality-adjusted life expectancy given stage II breast cancer with chemotherapy.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] WMJ. 1999 Dec;98(8):37-9 [10639893.001]
  • [Cites] J Gen Intern Med. 2005 Jan;20(1):38-44 [15693926.001]
  • [Cites] J Clin Oncol. 2000 Sep 15;18(18):3302-17 [10986064.001]
  • [Cites] Oncol Nurs Forum. 2000 Nov-Dec;27(10):1555-64 [11103374.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1455-61 [11230491.001]
  • [Cites] Br J Cancer. 2001 Jun 15;84(12):1577-85 [11401308.001]
  • [Cites] Natl Vital Stat Rep. 2001 Sep 21;49(8):1-113 [11591077.001]
  • [Cites] J Natl Cancer Inst. 2002 Mar 6;94(5):334-57 [11880473.001]
  • [Cites] J Natl Cancer Inst. 2002 Apr 3;94(7):471-3 [11929941.001]
  • [Cites] Cancer. 2002 Jun 1;94(11):2844-54 [12115371.001]
  • [Cites] Cancer. 2002 Oct 15;95(8):1759-66 [12365025.001]
  • [Cites] South Med J. 2002 Oct;95(10):1145-8 [12425498.001]
  • [Cites] Cancer. 2003 Jan 1;97(1):134-47 [12491515.001]
  • [Cites] Cancer Metastasis Rev. 2003 Mar;22(1):55-65 [12716037.001]
  • [Cites] Surg Clin North Am. 2003 Aug;83(4):803-19 [12875597.001]
  • [Cites] Breast Cancer Res Treat. 2003 Sep;81(1):21-31 [14531494.001]
  • [Cites] BMC Med Inform Decis Mak. 2001;1:2 [11545684.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):34-42 [14697418.001]
  • [Cites] J Gen Intern Med. 2004 Feb;19(2):184-94 [15009798.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1687-717 [15894097.001]
  • [Cites] Med Decis Making. 2005 May-Jun;25(3):301-7 [15951457.001]
  • [Cites] Arch Fam Med. 1999 Nov-Dec;8(6):521-8 [10575392.001]
  • [Cites] Med Decis Making. 2000 Jan-Mar;20(1):72-8 [10638539.001]
  • [Cites] Cancer. 2003 Jan 1;97(1 Suppl):311-7 [12491494.001]
  • [Cites] Arch Intern Med. 2003 Jan 13;163(1):49-56 [12523916.001]
  • [Cites] Ann Intern Med. 2003 Jan 21;138(2):90-7 [12529090.001]
  • [Cites] J Eval Clin Pract. 2003 Feb;9(1):69-82 [12558704.001]
  • [Cites] Med Decis Making. 2003 Mar-Apr;23(2):167-76 [12693879.001]
  • [Cites] Prev Med. 2004 Jul;39(1):1-10 [15207980.001]
  • [Cites] CA Cancer J Clin. 2003 Nov-Dec;53(6):342-55 [15224974.001]
  • [Cites] Clin Prostate Cancer. 2004 Jun;3(1):31-7 [15279688.001]
  • [Cites] Health Serv Res. 1972 Summer;7(2):118-33 [5044699.001]
  • [Cites] Med Decis Making. 1982 Winter;2(4):449-62 [7182703.001]
  • [Cites] J Health Econ. 1986 Mar;5(1):1-30 [10311607.001]
  • [Cites] Med Care. 1989 Mar;27(3 Suppl):S190-204 [2522159.001]
  • [Cites] J Natl Cancer Inst. 1989 Dec 20;81(24):1879-86 [2593165.001]
  • [Cites] N Engl J Med. 1993 Jul 29;329(5):326-31 [8321261.001]
  • [Cites] Med Decis Making. 1993 Jul-Sep;13(3):212-7 [8412549.001]
  • [Cites] Cancer. 1996 Oct 1;78(7):1395-402 [8839544.001]
  • [Cites] Breast Cancer Res Treat. 1996;39(3):261-73 [8877006.001]
  • [Cites] Breast Cancer Res Treat. 1996;40(1):65-74 [8888153.001]
  • [Cites] Am J Prev Med. 1996 Sep-Oct;12(5):327-37 [8909641.001]
  • [Cites] Med Decis Making. 1997 Jan-Mar;17(1):21-32 [8994148.001]
  • [Cites] Med Decis Making. 1997 Apr-Jun;17(2):136-41 [9107608.001]
  • [Cites] Oncol Nurs Forum. 1998 Apr;25(3):555-62 [9568610.001]
  • [Cites] Oncol Nurs Forum. 1998 Jun;25(5):887-95 [9644705.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 18;91(16):1409-15 [10451447.001]
  • [Cites] J Clin Epidemiol. 1999 Nov;52(11):1047-53 [10526998.001]
  • [Cites] Med Care. 2005 Feb;43(2):141-8 [15655427.001]
  • [Cites] Med Care. 2000 Sep;38(9 Suppl):II160-4 [10982102.001]
  • (PMID = 16961753.001).
  • [ISSN] 1525-1497
  • [Journal-full-title] Journal of general internal medicine
  • [ISO-abbreviation] J Gen Intern Med
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / K12 HD043447; United States / NICHD NIH HHS / HD / HD43447
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hormones; 0 / Receptors, Estrogen
  • [Other-IDs] NLM/ PMC1924747
  •  go-up   go-down


59. Yang JJ, Park SK, Cho LY, Han W, Park B, Kim H, Lee KS, Hahn SK, Cho SI, Ahn SH, Noh DY, Korean Breast Cancer Society: Cost-effectiveness analysis of 5 years of postoperative adjuvant tamoxifen therapy for Korean women with breast cancer: retrospective cohort study of the Korean breast cancer society database. Clin Ther; 2010 Jun;32(6):1122-38
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Women with stage I, II, or III breast cancer (diagnosed between 1981 and 2005), for whom information about tamoxifen use (20 mg/d for 5 years) and estrogen-receptor and/or progesterone-receptor status was available, were included.
  • Using a decision analytic model based on standard clinical flow, incremental cost-effectiveness ratios (ICERs) for overall survival were calculated with stratification by disease stage and hormone-receptor status.
  • Among those with stage I or II breast cancer, ICERs for estrogen-receptor positive (ER+)/progesterone-receptor positive (PR+) tamoxifen users ranged from $739 to $1939.
  • In contrast to those with stage I or II disease, tamoxifen use among patients with stage III disease was cost-effective regardless of hormone-receptor status.
  • CONCLUSIONS: In this analysis, postoperative adjuvant tamoxifen use was cost-effective for stage I or II ER+ and/or PR+ breast cancer, but not for ER-/PR- disease.
  • Tamoxifen therapy appeared to be cost-effective for patients with stage III breast cancer regardless of hormone-receptor status.
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Cohort Studies. Cost-Benefit Analysis. Female. Humans. Korea. Middle Aged. Neoplasm Recurrence, Local. Registries. Retrospective Studies

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20637966.001).
  • [ISSN] 1879-114X
  • [Journal-full-title] Clinical therapeutics
  • [ISO-abbreviation] Clin Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  • [Investigator] Ahn SH; Bae JW; Bae YT; Baek JW; Bong JG; Cha KH; Chang ES; Chang IT; Chang SS; Cho JW; Cho SH; Cho YU; Choi JW; Choi KJ; Choi MS; Choi SI; Choi SY; Goo GS; Han SH; Han W; Hong SJ; Hwang JY; Hyun TI; Im MG; Jegal YJ; Joh YG; Jun SY; Jung BW; Jung J; Jung JH; Jung KH; Jung PJ; Jung SH; Jung SS; Jung YH; Jung YS; Kang DH; Kang HJ; Kang YI; Kang YJ; Keum JH; Kim DY; Kim HJ; Kim JG; Kim JH; Kim JS; Kim JS; Kim KC; Kim SC; Kim SH; Kim SI; Kim SJ; Kim SW; Kim SW; Kim SY; Kim SY; Kim YS; Ko BK; Ko SS; Koh SH; Koo BH; Koo JY; Kwak BS; Lee CH; Lee CH; Lee DH; Lee DS; Lee ES; Lee GS; Lee HD; Lee HS; Lee JC; Lee JH; Lee JK; Lee JS; Lee JY; Lee KM; Lee KP; Lee KS; Lee KY; Lee MH; Lee RA; Lee SC; Lee SJ; Lee SK; Lee W; Lee YH; Leu JW; Lim CH; Lim CW; Moon BI; Nam SJ; Nam YS; Noh DY; Noh WC; Oh SJ; Oh SS; Pae WK; Paik IW; Paik NS; Park BG; Park BW; Park CH; Park HB; Park HY; Park JH; Park KH; Park SJ; Park ST; Park SW; Park WC; Park YK; Park YK; Seo HS; Seo KH; Seo YJ; Sin YS; Son BH; Son GS; Song BJ; Song KH; Song YJ; Suh YJ; Won JM; Woo DH; Yang DH; Yang JH; Yoo KY; Yoo SY; Yoon HS; Yoon JH; Yoon SO
  •  go-up   go-down


60. Kawamura A, Horie T, Tsuda I, Abe Y, Yamada M, Egawa H, Iida J, Sakata H, Onodera K, Tamaki T, Furui H, Kukita K, Meguro J, Yonekawa M, Tanaka S: Clinical study of therapeutic angiogenesis by autologous peripheral blood stem cell (PBSC) transplantation in 92 patients with critically ischemic limbs. J Artif Organs; 2006;9(4):226-33
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of 11 diabetic patients (DM) who were not receiving hemodialysis (HD), there were no amputees regardless of their Fontaine classification.
  • Of 19 patients in the HD(+)DM(-) category, there were no amputations in Fontaine stage I, II, and III patients, whereas three limbs and one toe were amputated in Fontaine stage IV patients.
  • Of 13 patients in the HD(-)DM(+) category, none of the Fontaine stage I, II, or III patients underwent amputation, but six Fontaine stage IV patients underwent amputation.
  • Of 49 patients in the HD(+)DM(+) category, 38 (78%) were classified as Fontaine stage IV, 71% (27/38) of whom had a toe or a limb amputated.
  • Therapeutic angiogenesis is effective for critically ischemic limbs resulting from hemodialysis and diabetes until Fontaine stage III, but is of limited effectiveness for stage IV cases.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diabetic Angiopathies / surgery. Diabetic Nephropathies / therapy. Female. Hematopoietic Stem Cell Mobilization. Humans. Male. Middle Aged. Plethysmography. Renal Dialysis. Thermography. Vascular Endothelial Growth Factor A / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Soc Nephrol. 2002 Feb;13(2):497-503 [11805180.001]
  • [Cites] Lancet. 2002 Dec 21-28;360(9350):2083; author reply 2084 [12504445.001]
  • [Cites] Lancet. 2002 Aug 10;360(9331):427-35 [12241713.001]
  • [Cites] Ther Apher Dial. 2005 Feb;9(1):59-63 [15828908.001]
  • [Cites] Ther Apher Dial. 2004 Feb;8(1):3-32 [15128016.001]
  • [Cites] Helv Chir Acta. 1954 Dec;21(5-6):499-533 [14366554.001]
  • (PMID = 17171401.001).
  • [ISSN] 1434-7229
  • [Journal-full-title] Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs
  • [ISO-abbreviation] J Artif Organs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


61. Tseng PL, Lu SN, Tung HD, Wang JH, Changchien CS, Lee CM: Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis. J Viral Hepat; 2005 Jul;12(4):386-92
Hazardous Substances Data Bank. LAMIVUDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Univariate analysis revealed that the total bilirubin (P = 0.008), prothrombin time (P = 0.004), Child-Turcotte-Pugh score (P = 0.005), the model of efd-stage liver disease score (P = 0.004) and stage III hepatic encephalopathy (P = 0.001) were predictive factors of early mortality.
  • Multivariate analysis revealed that the independent factor associated with early mortality was stage III encephalopathy.
  • [MeSH-minor] Adenine / analogs & derivatives. Adenine / therapeutic use. Adult. Aged. Drug Resistance, Viral / genetics. Female. Hepatic Encephalopathy. Hepatitis B virus / drug effects. Hepatitis B virus / genetics. Hepatitis B virus / isolation & purification. Humans. Male. Middle Aged. Mutation. Organophosphonates / therapeutic use. Survival Analysis. Taiwan

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Adefovir .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15985009.001).
  • [ISSN] 1352-0504
  • [Journal-full-title] Journal of viral hepatitis
  • [ISO-abbreviation] J. Viral Hepat.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Organophosphonates; 2T8Q726O95 / Lamivudine; 6GQP90I798 / adefovir; JAC85A2161 / Adenine
  •  go-up   go-down


62. Clark NA, Brincat CA, Yousuf AA, Delancey JO: Levator defects affect perineal position independently of prolapse status. Am J Obstet Gynecol; 2010 Dec;203(6):595.e17-22
MedlinePlus Health Information. consumer health - Pelvic Support Problems.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prolapse status was matched between groups, with 50% of the women having stage III or greater anterior wall prolapse.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Mosby, Inc. All rights reserved.
  • [Cites] Obstet Gynecol. 2005 Aug;106(2):315-20 [16055581.001]
  • [Cites] Ultrasound Obstet Gynecol. 2005 Jun;25(6):580-5 [15883982.001]
  • [Cites] Am J Obstet Gynecol. 2006 May;194(5):1427-33 [16579940.001]
  • [Cites] Obstet Gynecol. 2006 Aug;108(2):324-32 [16880302.001]
  • [Cites] Obstet Gynecol. 2007 Feb;109(2 Pt 1):295-302 [17267827.001]
  • [Cites] Kaohsiung J Med Sci. 2007 Jun;23(6):302-8 [17525015.001]
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 2007 Jul;18(7):773-8 [17043740.001]
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 2008 Jan;19(1):137-42 [17579801.001]
  • [Cites] Am J Obstet Gynecol. 2008 May;198(5):548.e1-6 [18455530.001]
  • [Cites] JAMA. 2008 Sep 17;300(11):1311-6 [18799443.001]
  • [Cites] Am J Obstet Gynecol. 2001 Jul;185(1):11-9 [11483897.001]
  • [Cites] Radiol Med. 2002 May-Jun;103(5-6):488-500 [12207184.001]
  • [Cites] Am J Obstet Gynecol. 2003 Jan;188(1):108-15 [12548203.001]
  • [Cites] Obstet Gynecol. 1998 Mar;91(3):364-8 [9491861.001]
  • [Cites] Am J Obstet Gynecol. 2005 May;192(5):1592-8 [15902163.001]
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 2005 Nov-Dec;16(6):432-6 [15660182.001]
  • (PMID = 20869037.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / P50 HD044406; United States / NICHD NIH HHS / HD / R01 HD038665; United States / NICHD NIH HHS / HD / P50 HD 44406
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS240000; NLM/ PMC3360540
  •  go-up   go-down


63. Peluffo MC, Barrett SL, Stouffer RL, Hennebold JD, Zelinski MB: Cumulus-oocyte complexes from small antral follicles during the early follicular phase of menstrual cycles in rhesus monkeys yield oocytes that reinitiate meiosis and fertilize in vitro. Biol Reprod; 2010 Oct;83(4):525-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The stage at which follicle-enclosed cumulus-oocyte complexes achieve developmental competence in primates is unknown.
  • Ovaries were removed from adult rhesus monkeys (n = 12) during the early follicular phase (Days 3-4) of spontaneous cycles.
  • Small antral follicles were divided into five groups according to their diameter; group I: <0.5 mm; group II: 0.5-0.99 mm; group III: 1.0-1.49 mm; group IV: 1.5-1.99 mm; and group V: 2.0-2.5 mm.
  • Moreover, the inseminated oocytes can reach the morula stage but arrest.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Reprod. 1985 Mar;32(2):413-7 [3986271.001]
  • [Cites] Hum Reprod. 1987 Aug;2(6):495-7 [3667906.001]
  • [Cites] Biol Reprod. 1988 Oct;39(3):546-52 [3196788.001]
  • [Cites] Biol Reprod. 1989 Aug;41(2):335-46 [2508776.001]
  • [Cites] Reprod Nutr Dev. 1989;29(5):523-31 [2513833.001]
  • [Cites] Mol Reprod Dev. 1990 Apr;25(4):374-83 [1691651.001]
  • [Cites] Biol Reprod. 1990 Apr;42(4):703-11 [2189504.001]
  • [Cites] Mol Reprod Dev. 1990 Jan;25(1):61-6 [2393585.001]
  • [Cites] Mol Reprod Dev. 1990 Nov;27(3):261-80 [2078341.001]
  • [Cites] Biol Reprod. 1991 Jul;45(1):89-93 [1878439.001]
  • [Cites] Biol Reprod. 1993 Feb;48(2):349-56 [8439624.001]
  • [Cites] Mol Reprod Dev. 1994 Apr;37(4):467-72 [8011332.001]
  • [Cites] Fertil Steril. 1994 Aug;62(2):353-62 [8034085.001]
  • [Cites] Biol Reprod. 1994 Nov;51(5):879-87 [7849190.001]
  • [Cites] N Engl J Med. 1999 Nov 18;341(21):1624, 1626 [10577135.001]
  • [Cites] Fertil Steril. 1999 Nov;72(5):845-51 [10560988.001]
  • [Cites] Hum Reprod. 2000 Jan;15(1):165-70 [10611207.001]
  • [Cites] Cancer Treat Rev. 1999 Dec;25(6):323-31 [10644499.001]
  • [Cites] Hum Reprod. 2000 Nov;15(11):2411-4 [11056143.001]
  • [Cites] Biol Reprod. 2001 Jul;65(1):253-9 [11420247.001]
  • [Cites] Reproduction. 2001 May;121(5):647-53 [11427152.001]
  • [Cites] Reproduction. 2001 Oct;122(4):587-92 [11570966.001]
  • [Cites] Fertil Steril. 2001 Nov;76(5):936-42 [11704114.001]
  • [Cites] Hum Reprod. 2002 Aug;17(8):2079-84 [12151440.001]
  • [Cites] Hum Reprod. 2002 Nov;17(11):2825-31 [12407033.001]
  • [Cites] Theriogenology. 2003 Feb;59(3-4):699-707 [12517374.001]
  • [Cites] Biol Reprod. 2003 Mar;68(3):812-21 [12604630.001]
  • [Cites] Hum Reprod. 2003 Apr;18(4):826-33 [12660279.001]
  • [Cites] Biol Reprod. 1994 Nov;51(5):904-12 [7849192.001]
  • [Cites] Hum Reprod. 1995 Apr;10(4):887-95 [7650138.001]
  • [Cites] Endocr Rev. 1996 Apr;17(2):121-55 [8706629.001]
  • [Cites] Mol Reprod Dev. 1996 Jun;44(2):193-9 [9115717.001]
  • [Cites] Reprod Fertil Dev. 1996;8(5):835-41 [8876042.001]
  • [Cites] Hum Reprod. 1996 Aug;11(8):1690-7 [8921118.001]
  • [Cites] Hum Reprod. 1996 Aug;11(8):1698-702 [8921119.001]
  • [Cites] Hum Reprod. 1997 Mar;12(3):403-5 [9130725.001]
  • [Cites] Fertil Steril. 1998 Jun;69(6):996-8 [9627281.001]
  • [Cites] Biol Reprod. 1998 Dec;59(6):1445-53 [9828191.001]
  • [Cites] Hum Reprod. 1998 Nov;13(11):3132-8 [9853870.001]
  • [Cites] Fertil Steril. 1999 Oct;72(4):639-42 [10521101.001]
  • [Cites] Hum Reprod. 1999 Oct;14(10):2544-55 [10527985.001]
  • [Cites] Mol Reprod Dev. 2005 Jul;71(3):358-67 [15822117.001]
  • [Cites] N Engl J Med. 2005 Jul 21;353(3):318-21 [15983020.001]
  • [Cites] Semin Reprod Med. 2005 Aug;23(3):234-41 [16059829.001]
  • [Cites] Anim Reprod Sci. 2007 Mar;98(1-2):56-71 [17081707.001]
  • [Cites] Tissue Eng. 2006 Oct;12(10):2739-46 [17518643.001]
  • [Cites] Biol Reprod. 2007 Jun;76(6):949-57 [17287496.001]
  • [Cites] Hum Reprod. 2007 Jul;22(7):1925-31 [17437960.001]
  • [Cites] Semin Reprod Med. 2007 Jul;25(4):287-99 [17594609.001]
  • [Cites] Hum Reprod. 2007 Aug;22(8):2232-42 [17562675.001]
  • [Cites] Reprod Sci. 2007 Dec;14(8 Suppl):6-10 [18089604.001]
  • [Cites] Curr Opin Endocrinol Diabetes Obes. 2008 Dec;15(6):514-22 [18971680.001]
  • [Cites] N Engl J Med. 2009 Feb 26;360(9):902-11 [19246362.001]
  • [Cites] J Reprod Dev. 2009 Feb;55(1):1-10 [19276618.001]
  • [Cites] Am J Primatol. 2009 May;71(5):384-92 [19189308.001]
  • [Cites] Pediatr Blood Cancer. 2009 Aug;53(2):289-95 [19301373.001]
  • [Cites] Biol Reprod. 2009 Sep;81(3):587-94 [19474063.001]
  • [Cites] Hum Reprod. 2009 Oct;24(10):2531-40 [19597190.001]
  • [Cites] Reprod Biomed Online. 2009 Sep;19(3):343-51 [19778479.001]
  • [Cites] Semin Reprod Med. 2009 Nov;27(6):443-9 [19806512.001]
  • [Cites] Semin Reprod Med. 2009 Nov;27(6):450-5 [19806513.001]
  • [Cites] Fertil Steril. 2010 Mar 15;93(5):1550-5 [19423101.001]
  • [Cites] Fertil Steril. 2010 May 1;93(7):2202-9 [19249763.001]
  • [Cites] Hum Reprod. 2003 Aug;18(8):1632-6 [12871873.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5307-14 [14602766.001]
  • [Cites] Reprod Biol Endocrinol. 2004 Jun 16;2:31 [15200680.001]
  • [Cites] Biol Reprod. 2004 Aug;71(2):486-93 [15044263.001]
  • [Cites] Hum Reprod. 2004 Sep;19(9):2109-17 [15243006.001]
  • [Cites] Lancet. 2004 Oct 16-22;364(9443):1405-10 [15488215.001]
  • [Cites] Lancet. 1965 Nov 6;2(7419):926-9 [4165802.001]
  • [Cites] J Exp Zool. 1974 Oct;190(1):123-7 [4436619.001]
  • [Cites] J Reprod Fertil. 1975 Oct;45(1):83-90 [1195259.001]
  • [Cites] J Reprod Fertil. 1977 Sep;51(1):1-15 [335057.001]
  • [Cites] Biol Reprod. 1982 Nov;27(4):989-97 [7171676.001]
  • [Cites] J Clin Endocrinol Metab. 1983 May;56(5):1022-31 [6403567.001]
  • [Cites] Biol Reprod. 1983 May;28(4):983-99 [6683110.001]
  • [Cites] Recent Prog Horm Res. 1983;39:1-73 [6415767.001]
  • [Cites] Dev Biol. 1984 Apr;102(2):493-7 [6706011.001]
  • (PMID = 20519694.001).
  • [ISSN] 1529-7268
  • [Journal-full-title] Biology of reproduction
  • [ISO-abbreviation] Biol. Reprod.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / RL1 HD058294; United States / NICHD NIH HHS / HD / U54 HD55744; United States / NICHD NIH HHS / HD / T32-HD007068-3; United States / NCRR NIH HHS / RR / P51 RR000163; United States / NICHD NIH HHS / HD / R01-HD058294; United States / NICHD NIH HHS / HD / RL1HD058295; United States / NCRR NIH HHS / RR / RR00163; United States / NIBIB NIH HHS / EB / PL1 EB008542; United States / NCRR NIH HHS / RR / K01 RR000163; United States / NIDCR NIH HHS / DE / UL1 DE019587; United States / NCRR NIH HHS / RR / UL1 RR024926; United States / NICHD NIH HHS / HD / RL1 HD058295; United States / NICHD NIH HHS / HD / U54 HD18185; United States / NICHD NIH HHS / HD / U54 HD055744; United States / NIDCR NIH HHS / DE / UL1DE019587; United States / NICHD NIH HHS / HD / T32 HD007068; United States / NCRR NIH HHS / RR / 1 UL1 RR024926; United States / NICHD NIH HHS / HD / U54 HD018185; United States / NIBIB NIH HHS / EB / PL1-EB008542
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2957158
  •  go-up   go-down






Advertisement